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Abstract 
Colorectal cancer remains a major cause of death and illness in Western society.  Although 
advances have been made in its management over the past 2 decades, many challenges with 
appropriate treatment targeting, diagnosis and management remain.  Addressing these 
challenges through the approach of ‘personalised healthcare’ is of increasing interest to 
researchers.  This has been facilitated by recent advances in metabonomic techniques.  This 
approach involves the investigation of metabolic consequences of disease downstream of the 
disease process, including the complex interaction between host and environment. 
Using 
1
H NMR spectroscopy, colorectal cancer tissue was analysed on patients operated on 
between 2007 and 2009.  The first study in this thesis identifies the metabolic phenotype 
associated with the disease, and attempts to relate this to what is known about colorectal and 
other cancer metabolism.  The second study utilises multivariate regression analysis to 
develop discriminatory models and panels of metabolites to differentiate between cancer 
stages and other clinical and pathological features of the tissue.  In the third study, this 
approach was applied to an in-vitro cell model of 5-FU chemotherapy resistance to determine 
the metabolic pathways associated with this resistance.   
A distinct metabolic profile discriminating normal from cancerous tissue was identified.  No 
such profile was able to discriminate tissue on the basis of cancer stage.  Discreet metabolic 
changes were associated with 5-FU chemoresistance but were too few to make assumptions 
about mechanism.   
Colorectal cancer joins other solid tumours in expressing a distinct metabolic phenotype and 
metabonomic techniques provide insight into the mechanisms underlying the disease.   
  
3 
 
The contents of this thesis are my own work.  Where work has been performed by or with 
other individuals they are credited within the text.   
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1 Introduction 
1.1 Current Challenges in the Management of Colorectal Cancer  
Colorectal cancer remains a major public health concern in the Western World.  In 2010 over 
40,000 new cases were diagnosed in the United Kingdom making it the fourth most common 
cancer in the UK after breast, lung and prostate cancer.
1
  Men and women are affected 
equally, and the incidence has a strong association with increasing age with 85% of cases 
being diagnosed in people over 60 years of age.  The mainstay of treatment is surgical, and 
with advances in surgical treatment options, even limited metastatic disease can be treated 
curatively with surgery.
2
  Nonetheless, although the mortality from colorectal cancer has 
improved considerably over the last few decades, it remains high and is the second most 
common cause of cancer deaths.
1
  Survival is strongly related to stage at diagnosis ranging 
from a five year survival of 7% for Dukes D tumours to 94% for tumours diagnosed at Dukes 
A stage.
3
 
The strong correlation between pathological stage at diagnosis and survival has led to efforts 
to improve the speed at which cancers are detected and diagnosed.  Initiatives such as the 
National Bowel Cancer Screening Programme, public awareness campaigns, and swifter 
access to diagnosis and treatment through central government initiatives are likely to improve 
survival further over the coming years.  Nonetheless, the efficacy and acceptability of these 
initiatives are imperfect and efforts continue to detect and treat cancer at an earlier stage.   
Despite improvements in detection and diagnosis, patients continue to present with advanced 
disease.  Chemotherapy and radiotherapy have an established role as adjuvant therapies in 
improving the survival of these patient groups.  “Although their effect on survival 
improvement is unequivocal in the patient groups as a whole, it remains that on an individual 
17 
 
level some patients who receive chemotherapy will not actually derive benefit from adjuvant 
treatment as their tumours may fail to respond to the agents available.  Equally, when given 
in stage II disease, it is likely that some of this group may have been cured by surgery alone 
4,5, 6. 
Given the cost both in terms of toxity to the patient and economic in regards to the health 
service as a whole, improvements in targeting those patients who would benefit from 
adjuvant therapy would clearly be advantageous.  To date however, appropriate targeting 
markers remain elusive.   
1.1.1 Natural History of Sporadic Colorectal Cancer – The Adenoma-Carcinoma 
Sequence 
To effectively target new biomarkers and therapies for CRC, a comprehensive understanding 
of the natural history of the disease is required.  It is now widely accepted that sporadic 
cancers arise through a progressive sequence of changes in the normal bowel mucosa to 
benign adenomatous polyps and thence onto adenocarcinoma through a series of well 
described genetic mutations.
7
   An understanding of this sequence has guided much of UK 
policy for the treatment and surveillance of both benign and malignant lesions.
8
 
Colorectal cancer arises from normal colonic mucosa, through the formation of adenoma and 
then on to carcinoma through a progressive genetic process involving a number of key 
genetic mutations.  This process is represented in Figure 1.1.  Both tumour suppressor genes 
as well as proto-oncogenes develop well described mutations.  Epigenetic phenomena such as 
hyper- or hypo-methylation of DNA lead to genomic instiablitiy that further increases the 
mutation rate and accelerates the process of carcinogenesis.
9
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Several different gene mutations have been identified.  One of the initial mutations thought to 
occur in the development of sporadic colorectal cancer is thought to be inactivation of the 
adenomatous polyposis coli (APC) gene, a tumour suppressor gene located on chromosome 
5q, first identified as a hereditary mutation in patients with familial polyposisis.
10
  Mutations 
in other tumour suppressor genes including SMAD2, SMAD4 and DCC on chromosome 18q 
have also been characterise but arise later than mutations in APC.
11
  The timing of these 
mutations can serve as an indicator of the degree of tumour development.  Mutations in the 
p53 gene, for example, a tumour suppressor protein that in humans regulates the cell cycle 
appear to occur at a later stage and as such interest has arisen in its use as a potential 
biomarker for invasive tumours in patients at risk of developing CRC such as those with 
ulcerative colitis.
12
  Mutations in the K-ras oncogene are thought to occur at an intermediate 
stage
13
 and are rarely found in association with p53 mutations suggesting alternative 
pathways to carcinogenesis.
14
  Many other genetic mutations have been observed in 
colorectal cancers none of which are seen in all cases.  As yet, there is poor definition of 
those mutations thought to allow metastases to develop although evidence exists that 
mutations in k-ras are associated with a poor prognosis even in lower stage disease, as well 
with advanced stage at presentation giving rise to its potential as a prognostic biomarker.
15
  
Epigenetic phenomena, the alteration of gene expression despite stability in the underlying 
DNA sequence, are another way in which colorectal cancer can develop through genomic 
instability.  One of the most characterised is microsatellite instability (MSI) a state in which 
mismatch repair (MMR) is disrupted.  Although this can occur in association with mutations 
in underlying MMR genes, in sporadic colorectal cancer these genes are usually not mutated 
and expression is reduced by hypermethylation of the promotor regions of hMLH1.
16
  As a 
result, MMR is reduced and the sporadic errors in the genetic sequence that occur as an 
occasional event in normal genetic replication are able to accumulate.
17
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Figure 1.1 - The colorectal adenoma-carcinoma sequence 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews in Cancer 
18
, 
copyright 2005. 
 
1.1.2 Staging of Colorectal Cancer 
The vast majority of colorectal cancers are adenocarcinomas with an unequal distribution 
throughout the lower gastrointestinal tract with the majority of  cancers occurring in the distal 
portion (Figure 1.2) 
19
.  Accurate staging is vital to characterise a patient’s prognosis and 
guide future management decisions and although tissue diagnosis can be confirmed from 
biopsies obtained during endoscopy, complete staging requires formal examination of the 
excised surgical specimen.   The two most commonly in use are the Dukes’ and TNM staging 
both of which rely on the assessment of local, lymphatic and distant tumour presence. 
20 
 
 
Figure 1.2 – Distribution of colorectal cancer within the large bowel  
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews in Cancer 
18
, 
copyright 2005. 
 
Originally developed for rectal cancers, the Dukes’ classification is now used for cancers of 
the entire large bowel and is the simplest in use (Table 1.1).  A number of different iterations 
have evolved in an effort to further refine the prognostic ability of the system but the most 
common in use is the 1935 modification, albeit originally defined for rectal cancers.
20
  Those 
cases confined to the bowel wall are ‘A’.  Extension beyond the outer limit of the muscularis 
propria are divided into those not involving the regional lymph nodes – ‘B’, and those in 
which the lymph nodes are involved – ‘C’.  C cases have been subsequently divided into 
those where the apical node (and therefore presumed residual nodes) are involved (C2) and 
those where the apical node is free of disease (C1).  Stage ‘D’ has been added to refer to 
those cases in which distant metastases are present.  Of note, the division of Dukes’ ‘C’ 
demonstrates the one of the potential inherent inconsistencies in the staging of surgical 
specimens:  whilst it is desirable to think of the stage of a tumour as an absolute – it can be 
21 
 
seen that for a particular case – the exact stage of the tumour will of depend on the extent of 
the surgical resection.  Nonetheless, it can be argued that incorporating treatment factors into 
the staging system can only improve risk stratification.  Most departments are now however 
moving towards the more detailed American Joint Committee on Cancer TNM staging (Table 
1.2). 
Whilst formal pathological staging requires examination of the removed surgical specimen, 
accurate pre-operative staging offers significant advantages in planning individual patient’s 
treatments and efforts directed towards improving the accuracy of radiological staging have 
resulted in significant advances in this field.  A recent meta-analysis of the diagnostic 
accuracy of CT in localised staging of colorectal cancer showed an 86% specificity and 78% 
sensitivity for accurately assessing extension of the tumour beyond the muscularis propria 
(T3/T4) but was poor at detecting nodal status.
21
  Positron emission tomography appears to 
offer no further advancement in the sensitivity in detecting positive lymph nodes
22
 but 
remains the most sensitive technique for detecting local and distant recurrent disease when a 
high index of suspicion exists.
23
   Nonetheless, there remains a need to further refine 
preoperative staging, particularly for rectal cancer where appropriate selection for 
preoperative therapy as well as choice of surgical procedure offers real improvements in 
outcome.
24
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Modified Dukes’ classification of colorectal cancer 
 A Growth limited to bowel wall 
 B Extension of growth through bowel wall 
 C1 Apical node is not involved (but proximal nodes are) 
 C2 Apical lymph node is involved 
 D Distant metastasis present 
Table 1.1 - Modified Dukes’ classification of colorectal cancer20  
 
TNM Classification of Colorectal Cancer 
T- Primary tumour 
 Tx Primary tumour cannot be assessed 
 T0 No evidence of primary tumour 
 Tis 
 
 
Carcinoma in situ: intraepithelial or invasion of laminal 
propria (intramucoxal) without extension through muscularis 
mucusae into submucosa 
 T1 Invades submucosa 
 T2  Invades muscularis propria 
 T3 Invades beyond muscularis propria into subserosa or 
mesenteric tissues 
 T4 Invades other organs and/or perforates visceral peritoneum 
N – Regional lymph nodes 
 Nx Cannot be assessed 
 N0 No regional lymph node metastasis 
 N1 Metastasis in 1-3 regional lymph nodes 
 N2 Metastasis in 4 or more regional lymph nodes 
M – Distant Metastasis 
 Mx Cannot be assessed 
 M0 No distant metastasis 
 M1 Distant metastasis present 
Table 1.2 - TNM staging of colorectal cancer
25
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1.1.3 Treatment of Localised Disease 
Colon Cancer 
Surgical treatment choices for cancer of the intra-peritoneal colon is relatively 
straightforward with treatment decisions related largely to the extent of the resection that 
should be performed with reference to the blood supply of the bowel.  The aim for all cancer 
surgery is an R0 resection – one which leaves no microscopic tumour – with tumour free 
margins either side of the lesion.  There is no evidence that preoperative radio- or 
chemotherapy offer any benefit and resectable tumours are treated with surgery alone unless 
as  part of a clinical trial. 
26
 
Rectal Cancer 
Unlike cancer of the intra-peritoneal colon, where local recurrence is infrequent, cancers 
arising in the rectum can result in significant recurrence rates even after surgical resection 
that appeared to be curative.  Local recurrence is closely related to stage at presentation, 
ranging from 3% for Dukes A to 19% for Dukes C 
27
.  In addition, the anatomical location of 
the rectum deep in the pelvis gives rise to a higher chance of positive circumferential 
resection margin despite the development of surgical techniques to allow total mesorectal 
excision (TME).  Multi-modality treatment of rectal cancer consisting of surgery with 
chemotherapy and or radiotherapy delivered either pre- or post-operatively can therefore be 
offered with broadly 2 aims: 
1) To downstage an apparently unresectable (locally advanced) cancer prior to surgery 
with the intent of obtaining an R0 resection. 
2) To reduce the risk of local recurrence in a tumour that appears to be at high risk of 
local recurrence following surgery.  
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Locally Advanced Rectal Cancer 
Although the concept of locally advanced rectal cancer is not universal, pre-operative MRI 
scanning has demonstrated a 92% specificity in predicting clear circumferential resection 
margins and as a result  is now part of  routine pre-operative workup for rectal cancers in this 
country.
28,26 
  Both  pre-operative radiotherapy and chemoradiotherapy have demonstrated the 
ability to downstage tumours in order to obtain a clear resection margin at subsequent surgery 
and although there is little good quality data comparing neoadjuvant treatment with surgery 
alone, both appear to offer a disease specific survival benefit. 
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30
  When chemoradiotherapy 
and radiotherapy alone are compared, little difference is observed in overall survival but 
disease specific survival and local recurrence is lower following chemoradiotherapy. 
31,32 
  As 
a result, patients in the UK with locally advanced tumours are routinely offered 
chemoradiotherapy followed by restaging prior to surgery or, where unfit, preoperative 
radiotherapy alone.
26
   
Localised Rectal Cancer 
The most recent National Bowel Cancer Audit reveals that nearly 8% of surgical specimens 
have a positive circumferential margin and although causation is not clear, it seems likely that 
this is due to radiological under-staging. Furthermore, a number of patients in whom an R0 
surgical resection is achieved will go on to develop local recurrence at a later date.  There is 
good evidence that patients with apparently clear circumferential margins on MRI can derive 
considerable benefit from preoperative chemotherapy and or radiotherapy.   A large meta-
analysis of 22 randomised controlled trials convincingly demonstrated a 46% reduction in the 
annual risk of recurrence in those patients undergoing pre-operative radiotherapy compared 
to surgery alone as well as a 5% improvement in overall survival.
33
  In the UK when given 
alone preoperatively, radiotherapy is usually given as a short course (SCRT), with a relatively 
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high radiation dose per fraction given over a 5 day period immediately prior to surgery and 
appears to offer equivalent benefit to full course chemo-radiotherapy.
34
 
However, both radiotherapy and chemotherapy can give rise to significant short-term side 
effects as well as long term morbidity in patients.  The most common immediate side-effect 
following radiotherapy is diarrhoea and occurs in up to 17% of patients.
30
  In the longer term 
patients undergoing preoperative radiotherapy have poorer bowel function with high rates of 
incontinence reported as well as increased stool frequency and urgency compared with 
patients undergoing surgery alone
35
 and sexual function is significantly poorer. 
36
  There is 
less data on the long term side effects following full course chemo-radiotherapy but where 
available appears to give rise to a similar late effects profile as SCRT given alone.
37
  When 
given in conjunction with chemotherapy, although late effects appear to be similar, acute 
grade II and IV acute treatment related toxicity is significantly more pronounced.
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Risk Stratification of Localised Rectal Cancer 
Given the morbidity associtated with pre-operative radio- and chemotherapy, efforts are made 
to identify and offer it to those patients most likely to benefit.  The National Institute of 
Clinical Excellence (NICE) has produced guidelines, stratifying patients into three groups of 
risk for local recurrence based on findings at preoperative MRI scan (Table 1.3).  Dependent 
on the risk stratification patients will be considered for surgery alone, SCRT followed by 
surgery or a full course of chemoradiotherapy followed by surgery.  Broadly, pre-operative 
SCRT is offered to those patients with apparently surgically resectable disease who are at 
high risk of recurrence and longer course chemo-radiotherapy is offered to those patients with 
clear or threatened positive margins on pre-operative MRI scanning (Table 1.4).
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Despite this, the numbers needed to treat to derive benefit are significant and the majority of 
patients treated will not achieve any benefit despite potentially experiencing the unwanted 
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effects of treatment.  For example, a Dutch RCT compared 622 patients with stage III (N1-2, 
M0) rectal cancer, randomized to SCRT and TME or TME alone.  5 year risk of relapse with 
local recurrence was 10.6% in the group assigned to SCRT prior to surgery and 20.6% in the 
TME only arm of the study.  As a result, in order to prevent one disease recurrence at 5 years, 
10 patients must undergo SCRT.  The equivocal disease specific survival data gives rise to 
even higher numbers needed to treat in order to prevent one disease specific death.
38
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Risk of local 
Recurrence 
Characteristics of rectal tumours predicted by MRI 
High  a threatened (<1mm) or breached resection margin or 
 low tumours encroaching onto the inter-sphinchteric plane or 
with levator involvement 
Moderate  Any cT3bi,ii or greater, in which the potential surgical margin is 
not threatened or 
 Any suspicious lymph node not threatening the surgical 
resection margin or 
 the presence of extramural vascular invasioniii 
Low  cT1 or cT2 or cT3a and 
 no lymph node involvement 
Table 1.3 – Risk of local recurrence for rectal tumours as predicted by MRI 
From National Institute for Health and Care Excellence (2011). Colorectal cancer: The 
diagnosis and management of colorectal cancer. 
39
  Copyright NICE (2011). 
  
                                                 
i
 The prefix –c denotes the stage is clinical or preoperative in contrast to that obtained by 
pathological examination.  
ii
 Tumour stage 3 (T3) is subdivided by the depth of invasion into the subserosa or perirectal 
tissue:  
T3a <1mm,  
T3b 1-5mm  
T3c 5-15mm  
3d >15mm.     
 Although not adopted by the American Joint Committee on Cancer Staging it is 
recommended by the  European Society of Medical Oncology on the basis that depth of 
invasion correlated with prognosis.   
iii
 Associated with a high risk of systemic recurrence 
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Recommendations 
 Discuss the risk of local recurrence, short-term and long-term morbidity 
and late effects with the patient after discussion in the multidisciplinary 
team (MDT). 
 Do not offer short-course preoperative radiotherapy (SCPRT) or 
chemoradiotherapy to patients with low-risk operable rectal cancer  unless 
as part of a clinical trial. 
 Consider SCPRT then immediate surgery for patients with moderate-risk 
operable rectal cancer. Consider preoperative chemoradiotherapy with an 
interval to allow tumour response and shrinkage before surgery for patients 
with tumours that are borderline between moderate and high risk. 
 Offer preoperative chemoradiotherapy with an interval before surgery to 
allow tumour response and shrinkage, (rather than SCPRT) to patients 
with high-risk operable rectal cancer. 
Table 1.4 – NICE Treatment Recommendations for Localised Rectal Cancer 
From National Institute for Health and Care Excellence (2011). Colorectal cancer: The 
diagnosis and management of colorectal cancer. 
39
 Copyright NICE (2011).  
 
Surgical Strategy 
As discussed, surgical resection of the intraperitoneal colon well established and other than a 
significant shift towards laparoscopic surgery, the extent of surgical resection has evolved 
little of the years.  Conversely, the surgical resection for rectal cancers has shifted from the 
abdomino-perineal excision, previously regarded as ‘gold standard’.  Now,  low and ultra-low 
anterior resection with total mesorectal excision (TME) are employed for increasingly distal 
tumours allowing the sphincters to be preserved, even in those tumours who appear to 
threaten the intersphinchteric plane on pre-operative MRI.
40
 
Local excision including transanal resection and transanal endoscopic microsurgery (TEM) 
are other surgical options that can be used to treat low rectal cancers without disrupting 
sphincter function.   Originally developed for local symptomatic control in patients who were 
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unsuitable for trans-abdominal surgey, these techniques may be curative in a carefully 
selected population. 
Malignant Polyps 
With the rollout of the NHS Bowel Cancer Screening Programme, two  forms of early 
colorectal cancer are increasingly being identified: carcinoma in situ – an adenoma 
containing severe dysplasia, and malignant polyps.  The latter are defined as an adenoma in 
which cancer has invaded by direct continuity through the muscularis mucosa into the 
submucosa.
41
  Whilst carcinoma in situ is managed by endoscopy alone followed by 
surveillance, the management of malignant polyps is more controversial depending on the 
risk of residual or recurrent disease.  No randomized controlled trials have compared 
polypectomy alone with surgical resection and efforts are therefore directed towards 
retrospective analysis of data in an effort to identify risk factors for residual or recurrent 
disease and stratify these early cancers into ‘low-‘ or ‘high-risk’.    
A positive resection margin has shown to be associated with higher risk of residual or 
recurrent disease
42
 as has a histological grade of III or higher.
43
  In addition, the depth of 
malignant invasion into the polyp correlates with the risk of recurrence measured by Haggit 
or Kicuchi level in the case of pedunculated and sessile polyps respectively.
44, 11
  Whilst the 
Haggitt level classifies cancers into the depth of invasion into the head, neck, stalk or base of 
a pedunculated polyp, Kikuchi classifies sessile polyps on the basis of the malignant cell 
invasion into the polyp devided into the upper (Sm1), middle (Sm2) and lower (Sm3) third of 
the polyp
45
 (Figure 1.3).  In general, a clear resection margin, Haggit level <4 or Kikuchi 
<Sm3 and histological grade <III are considered low risk and can be safely managed with 
endoscopic resection.
46,47, 48
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Figure 1.3 – Haggitt level classifying the level of vertical invasion of a malignant polyp. 
Reprinted by permission from John Wiley & Sons.  Colorectal Disease 
45
. Copyright 2001, 
John Wiley and Sons. 
 
High-risk polyps are usually considered for surgery in a multi-disciplinary setting taking into 
account the risk of surgery and the patients’ wishes.49   They carry a high risk of residual 
disesase compared to low-risk polyps but with current practice many may still undergo 
surgery who would have been cured with endoscopy alone:  The Northern Colorectal Cancer 
Audit Group recently published a retrospective analysis of 386 patients of whom 71 
underwent surgical resection following apparently complete endoscopic excision.  In this 
group, 82% of patients had no evidence of tumour in the resected specimen.  2 of the patients 
who underwent surgical resection went on to develop recurrent disease (3%) compared to 5 
patients in whom polypectomy had been performed as definitive treatment (4%).  Although 
case selection makes it impossible to draw definitive conclusions from this retrospective 
analysis, it may be that the number of patients actually deriving benefit from surgical 
resection is limited to those who have demonstrated residual disease following a margin free 
polypectomy – in this series 18%.  Given the morbidity and mortality of elective bowel 
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resection therefore it has been suggested that rectal cancer in particular may be somewhat 
overtreated and more specific predictors of high risk polyps may be useful.
50
   
As local resection carries a significant risk of recurrence, patients undergoing this treatment 
must receive close follow-up to detect any evidence of recurrence at an early stage.  This may 
include clinical assessment such as rectal examination and proctoscopy, measurement of 
available tumour markers such as CEA and potentially imaging such as transanal 
ultrasonography as they may be candidates for resection in the presence of local recurrence.  
If a recurrence is detected, patients may be offered ‘salvage surgery’ in the form of a 
transabdominal resection but despite careful vigilance to detect early recurrence these 
patients have poorer outcomes than those undergoing primary surgical ressection.
51
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1.1.4 Adjuvant Chemoradiotherapy for Colorectal Cancer 
Adjuvant therapy for rectal cancer may be directed towards local control of disease or the 
treatment of systemic disease.  In rectal tumours, wide variations in local recurrence and 
survival of disease treated with surgical resection alone have been seen dependent on disease 
stage.  In a retrospective analysis, the Mayo Clinic reported a 5 year overall survival rate of 
79% for node negative cancers (all T stages) falling to 33% for N1 cancers and 7% for N2 
cancers in 512 patients treated with surgery alone
52
   
Several trials demonstrated a disease free survival benefit to post-operative chemotherapy 
either alone or in combination with radiotherapy. 
53, 54, 55
  5-fuoroucacil forms the basis of 
most adjuvant chemotherapeutic regimens where it confers a 5-10% improvement in absolute 
survival over surgical resection alone.
4
  Patient selection however is controversial and the 
evidence equivocal.  It is generally accepted that in the absence of contraindications, patients 
with stage III (N1-2) disease are offered adjuvant therapy although the benefit for elderly 
patients is disputed.
56
 
57
   More controversial however, is the role of adjuvant chemotherapy 
in stage II (N0) disease.  No clear evidence exists as to which patients in this group will 
benefit
58
 although a number of clinical and pathological features such as perforation, poor 
differentiation, the presence of signet cells and extramural vascular invasion are known to 
confer a worse prognosis and are often offered adjuvant treatment.
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1.1.5 Resistance to 5-Fluorouracil 
5-Fluorouracil is often given for the adjuvant treatment of colorectal cancers.  When given 
alone however, 5-FU has a relatively low overall response rate and is therefore usually given 
in combination with other agents.  Patients with metastatic disease treated with single agent 
5-FU show a response rate of 10-20% and concern arises that similar lack of response for 
micrometastatic disease could reduce the efficacy when used in an adjuvant setting.
59
  This 
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low response rate associated with morbidity from the treatment side effects as well as the 
socio-economic cost of treatment, has led to interest in identifying biomarkers to predict 
response to therapy.  Thymidilate synthase, the enzyme targeted by the drug, appears to be 
the most promising biomarker predictive of response to 5-FU.  Although high levels of the 
enzyme have been shown to be associated with worse outcome in both metastatic and early 
CRC, the results of retrospective analyses have been conflicting.  This, along with the lack of 
a standardised assay for its measurement have prevented the European Group on Tumour 
Markers recommending its measurement in routine clinical use.
60
    
A full understanding of the mechanisms underlying chemoresistance and in particular, 
resistance to 5-FU remains elusive however some understanding has developed over the 
recent years.    In an in-vitro cell line model, high expression of cyclin D, thymidine synthase, 
thymidine phosphorylase, and dihydropyrimidine dehydrogenase were identified as being 
associated with non-response to 5-FU in a colorectal cancer cell line
61, 62
 and has led to the 
proposition of novel genetic biomarkers for colorectal cancer.
63
  Another group identified 
TFAP2E hypermethalation to be associated with non-responsiveness and further 
characterised this as being mediated through increased levels DKK4 therefore identifying a 
futher putative biomarker.
64
   Despite these findings however, effective biomarkers for 
predicting therapeutic response remain elusive and the subject of much work.
65
    
1.1.6 Screening for Colorectal Cancer 
An understanding of the natural progression of the disease combined with the striking 
variation in survival by stage at diagnosis has driven the desire to diagnose colorectal cancers 
early, ideally at a pre-clinical stage.  The identification and removal of benign adenomatous 
polyps is known to reduce the subsequent incidence of CRC by up to 90%.
66
  Even for those 
patients in whom disease has already progressed to cancer, prompt identification of the 
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disease at an early stage, before metastasis can improve survival. 
67
  For this reason, 
screening programs for the early detection of colorectal cancer have become a priority of 
public health programs both in the United Kingdom and elsewhere.  The advantages 
conferred by a screening program are most evident for those at highest risk of developing 
CRC but average-risk patients derive some benefit.
68
 The healthcare system as a whole also 
benefits as screening programmes have been shown to reduce the overall cost of colorectal 
cancer treatment.
69
 
Screening programs vary both in terms of target population and methods used as no single 
method is suitable for all patient groups.  As the desire is to diagnose the disease at a pre-
clinical stage, clinical assessment is, by definition unhelpful so various investigative tests are 
used instead.  A number of different investigations can be employed in screening 
programmes.   
One of the least invasive and most widely studied screening tests is Haemoccult – a guiac 
faecal occult blood test that detects haematin activity in faeces.  As a ‘point of care’ test it can 
be interpreted immediately and is easy to perform. However, the test demonstrates sensitivity 
that can be as low as 50-70% depending on how many times it is repeated.
70
 It is currently the 
test used by the UK Cancer Screening Program where it is repeated three times, in duplicate.  
HemoQuant is sensitive to porphyrin and as such is able to quantify the amount of 
haemglobin in the stool.  Consequently it demonstrates a higher sensitivity but the inability to 
discriminate an upper gastrointestinal tract source and sensitivity to false positives due to 
exogenous blood e.g red meat render it unsuitable for routine use in screening for lower 
gastrointestinal tract malignancies.
71
  Faecal Immunochemical Tests are a newer method and 
rely on immunochemical testing to detect the globin portion of haemoglobin.  As globin does 
not survive passage through the gastrointestinal tract the test is more specific to lower 
gastrointestinal bleeding and also appears to offer advantages in sensitivity over guaic based 
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tests. In addition, they do not require dietary restrictions such as eliminating read meat from 
the diet prior to performing the test.
72
   
Double-contrast barium enema has now been largely superceded by flexible sigmoidoscopy, 
and colonoscopy in screening programmes either alone or in combination with a ‘risk-
stratification’ test such as FOBT as in the UK program.  These modalities have been subject 
to randomized controlled trials, where they appear to be less sensitive and specific than 
colonoscopy.
73
  In the USA, colonoscopy has been shown to safely detect many cancers in a 
screening population that would otherwise be undetected by sigmoidoscopy.
74,75
 Colonoscopy 
however has an increased risk of complications such as perforation, and generally requires 
more sedation than sigmoidoscopy and furthermore is associated with higher costs than less 
invasive methods 
76
. 
CT virtual colonoscopy (CTVC) is a newer tests for CRC which although available, is not yet 
used for screening .  A randomized controlled trial comparing CT Virtual colonoscopy with 
colonoscopy revealed a significantly higher diagnostic yield with colonoscopy but the uptake 
in patients invited for this screening test was significantly lower than that seen in those 
invited for the less invasive investigation.
77
  A trial of CTVC in a group of asymptomatic 
average-risk patients, reported a sensitivity of 89% and a specificity of 80% for polyps larger 
than 6 mm, with better results observed for polyps larger than 10 mm
78
 - equivalent to those 
seen in optical colonoscopy but others have reported significantly lower sensitivity.
79
  When 
considered alongside the issue that patients with lesions detected still require formal 
colonoscopy to obtain a tissue diagnosis and potentially treat, these conflicting findings 
suggest that virtual colonoscopy cannot yet be recommended as a routine screening modality.   
Knowledge of CRC genetics has led to the development of faecal DNA assays that test for 
mutations in multiple genes known to be involved in colorectal neoplasia and are currently 
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being evaluated in clinical trials.
80
 Whilst these assays have yet to be shown to have 
comparable sensitivity with more established screening methods they may be useful in 
patients who are not suitable for more invasive methods. 
Many countries have adopted CRC screening programs, but differ in their methodology and 
target population, usually by age.  Clearly, the development of an effective screening 
program for CRC requires an appropriate test and must balance a number of factors 
concerning both the efficacy of the test weighed against the costs – financial, medical and 
social of the test and program as a whole.
67
  The World Health Organisation published 
guidelines related to the principles of screening, which summarise those challenges (Table 
1.5)  
The American Cancer Society for example recommends that screening begin at age 50 for 
average-risk (general) polulation and recommends a choice of testing schedules from 
colonoscopy every 10 years to annual guiac based faecal occult blood testing.
81
 The UK NHS 
Bowel Cancer Screening Programe is offered from age 60 to 74 and consists of a guaiac-
based faecal occult blood test every two years with a referral for colonoscopy if positive.
82
  
Notably the UK programme specifically excludes those patients at high risk of CRC e.g. 
those with previous positive cancer or polyps or those with strong family histories. 
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Principles and Practice of Screening for Disease 
1 The condition should be an important health problem 
2 There should be a treatment for the condition 
3 Facilities for diagnosis and treatment should be available 
4 There should be a latent stage of the disease 
5 There should be a test or examination for the condition 
6 The test should be acceptable to the population 
7 The natural history of the disease should be adequately understood 
8 There should be an agreed policy on whom to treat 
9 The total cost of finding a case should be economically balanced  
10 Case-finding should be a continuous process 
Table 1.5 - World Health Organisation guidelines for a disease screening programme
83
 
From Wilson JMG, Jungner, G. Principles and Practice of Screening for Disease. Geneva: 
World Health Organisation, 1968. 
 
1.1.7 Summary 
The preceding sections have outlined some of the current challenges in the management of 
colorectal cancer.  One of the greatest of these is in targeting the right therapy to the right 
patient – the concept of  ‘personalised healthcare’.  Failing to deliver the correct treatment 
may result in increased morbidity and mortality either due to the lack of benefit of an 
adjuvant therapy or due to the side effects of an unnecessary treatment.  A multitude of 
factors are considered in determining the optimal treatment for any given patient and novel 
biomarkers may offer additional information for treatment targeting.  
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1.2 Metabonomics 
In recognition of the complex and interactive nature of the pathways underlying the function 
of all organisms, scientists have increasingly used systems biology approaches to advance 
their understanding of health and disease.  Utilising a holistic approach, the discipline 
attempts to examine the system in question as a whole rather than a reductionist approach that 
attempts to study individual components of these pathways.  The emergence of the ‘-omics’ 
technologies in recent decades has been facilitated by advances in both high throughput 
technologies, such as DNA microarrays, which allow a large number of biological endpoints 
to be measured simultaneously as well as advances in computing power and mathematical 
modelling to interpret the vast datasets that these techniques produce.
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Unlike more traditional scientific methods where particular genes, proteins or substrates are 
measured in different experimental conditions, ‘-omics’ techniques analyse the entire system 
in question, usually under multiple conditions, yielding a vast number of endpoints; the data 
is then analysed looking for trends and patterns.  This methodology leads to a difference in 
the way the scientific question is constructed.  In traditional scientific methodology, first a 
hypothesis is generated and subsequent experiments test that particular hypothesis.  In ‘-
omics’ science,  data can be collected without a pre-existing hypothesis and trends and 
patterns found following its analysis can then be used to generate a novel question which may 
then be tested using the most appropriate experimental platforms. Analysis of those systems 
lying near the top of the biological hierarchy – the genome, transcriptome and proteome is 
now well established, but more recently has attention turned to the end-point of this hierarchy 
– the metabolome.   
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1.2.1 The metabolome 
The metabolome refers to the complete set of low molecular weight metabolites found in a 
given organism.
85
  As it represents the end-point of biological processes it is most closely 
related to phenotype and function.  If the genome is considered the ultimate potential of the 
organism in question, examining the information further downstream in the hierarchical 
function of that organism can reveal what actually is happening rather than the biological 
potential that it holds (Figure 1.4). 
 
 
Figure 1.4- The biochemical hierarchy of cellular processes 
Moving down the biological hierarchy from genome to metabolome reveals information more 
related to the actual function of an organism at a moment in time rather than the potential it 
holds or the direction it is moving in.   
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The metabolome is dynamic and constantly changes in response to the host organism in the 
same way as the transcriptome and proteome.  Metabonomics has been defined as ‘the 
quantitative measurement of the multiparametric metabolic response of living systems to 
pathophysiological stimuli or genetic modification’.86 This emphasis on ‘quantative 
measurement’ sets this term subtlety apart from the broader field of metabolomics along with 
the fact that metabonomics is principally concerned with the biological response to an event 
such as a disease or external stressor.  This characteristation provides a number of 
opportunities for scientific discovery.  For example, by identifying patterns of similarities 
between disease or other measurable states in a group of organisms, it is possible to obtain 
clues about the underlying biochemical process without a priori knowledge of these 
processes for example revealing potential therapeutic targets in disease.   
Metabonomics can also be used to provide sample or subject classification – without 
necessarily seeking to understand the underlying reasons why a particular configuration of 
metabolites exists within a sample – known as metabolic fingerprinting. 87  This technique, 
with its potential to identify the emergence of distinct patterns between disease states, 
sensitivity to therapy or prognosis, for example, can reveal a potential biomarker or panel of 
biomarkers where the pattern exists with enough sensitivity and specificity.  In animal 
studies, the low molecular weight of  the metabolites detected by most analytical platforms 
used in sample analysis means that they pass easily into the animals biofluids such as plasma 
and urine and can therefore be collected relatively non-invasively.  As they are soluble in 
these biofluids, relatively little sample preparation is required and consequently a large 
number of specimens can be collected and prepared quickly.  In addition, because this 
technique involves the quantitative measurement of biological endpoints, it may be possible 
to track these endpoints through time in order to monitor the progression of a disease or 
predict clinical outcome.  
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1.2.2 Analytical platforms 
A number of different analytical platforms exist for the detection of these low molecular 
weight metabolites, each with its own advantages and disadvantages.  The most commonly 
used are mass spectrometry (MS) and nuclear magnetic resonance spectroscopy (NMR), the 
latter having the advantage that a separation step is not required and therefore less sample 
preparation is required.   
The principle techniques used in metabonomics for sample analysis are those of High 
frequency Magnetic resonance spectroscopy (H
1
NMR). NMR has the ability to detect and 
characterise many thousands of endogenous molecules simultaneously even when their 
chemical identities are unknown.  It requires little sample preparation and is non-destructive 
to intact biomaterials lending itself well to studying surgical disease where tissue specimens 
are often precious.
88
  
Mass Spectrometry (MS), which is more sensitive than NMR but gives poorer pattern 
quantification, is also used. MS generally requires a separation step using either Gas 
chromatography (GC), Liquid chromatography (LC) or chemical derivization before the MS 
stage. High performance Liquid Chromatography (HPLC) and optical spectroscopic 
techniques are other procedures with similar properties.  
1.2.3 Metabonomic data 
The techniques described above give rise to an enormous dataset of biological information 
and it is impossible to extract the relevant information manually. There are three principle 
steps to interpreting the data.  Firstly the raw data must be converted to a suitable form. 
Secondly the data is reduced so that only the most relevant input variables are used in the 
subsequent data analysis. Finally univariate or multivariate statistical analysis  of the reduced 
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data attempts to find patterns which can give useful biological information.  This information 
is used to generate a hypotheses that can be further tested on subsequent data.
89
     
NMR and MS are far from new technologies and have been used since the 1960s to 
investigate numerous cancers in human clinical trials.  Whilst these have eluded to the 
potential of metabonomics
90-94
, they have not had a significantly high impact because until 
recently there was not the bioinformatic armoury to interpret the data accurately. Cancer 
research through the last decade has therefore been focused on studying the organism at the 
genomic and proteomic level and consequently undervalued the role of the environment in 
the disease process. Metabonomics allows us to definine this relationship in ways that the 
other ‘–omics’ sciences are unable to do.95  
1.2.4 Applications of Metabonomics 
Metabonomics has recently begun to demonstrate its potential in the diagnosis and 
management of malignant disease.   Researchers from other centres have already been 
successful in diagnosing diseases in exactly this way.  A research group from Buffalo, New 
York have demonstrated that Nuclear Magnetic Resonance based metabonomics can be 
successfully used to detect ovarian cancer by discriminating between serum samples.
91
  
Another group used urine samples to successfully differentiate between patients with liver 
cancer and normal controls.
94
  It has already been demonstrated that cancerous colonic 
epithelium expresses different proteins to normal mucosa
96
  but to date, no group have 
attempted to use metabonomic techniques to characterise how the metabolism of cancerous 
colonic epithelium may be different from normal tissue. 
There is also increasing potential for its role in epidemiological studies, and it has been 
possible to type entire populations based on metabonomic data, probably on the basis of their 
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genetic variation, but certainly there is a cultural and dietary element.
97
  The hope is that 
these techniques can be developed to study disease at a large population level.  
1.3 Published Metabonomic Studies of Human Colon Cancer 
Although the number of studies investigating metabonomics in bowel cancer is relatively 
small it has been accelerating in recent years along with  those of various other solid tumours.  
A number of recent ex-vivo studies have been published over the last 5 years reporting 
metabonomic experiments on colorectal cancer utilising a variety of investigatory platforms 
and on various tissue types including blood, urine, tissue and stool.  The heterogeneity in 
study design along with the intrinsic sensitivity of the metabolic phenotype to the 
environment means that a distinct metabolic phenotype for the disease has been slow to 
materialise; nonetheless, a number of themes are emerging.    
In interpreting the published data on the subject, attempting to collate information from 
different studies and in particular comparing results across studies it is essential to have an 
awareness of both the experimental conditions and the precise definition of the primary 
endpoint.  For example, when comparing cancerous with normal tissue, investigators may 
define normal tissue as that taken from a healthy control subject or histologically normal 
tissue taken from a subject with bowel cancer.   
Caution is also required when interpreting studies that purport to discriminate between 
endpoints based on metabolic data.  The complexity of most of the statistical modelling 
techniques used in chemometrics means that they are prone to overfitting.  Whilst cross-
validation can be employed to determine the validity of the model, only a model that has been 
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validated with an external data set i.e. a data set not used to construct the initial 
discriminatory model can be considered truly valid.   
In the following section, a systematic review of the published literature to date is undertaken 
along with a data synthesis of the published and supplementary data where available. 
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Study Platform Subjects & Samples Metabolite changes in 
cancer 
TISSUE 
Mal  
(2012)
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GCxGC/TOFMS 33 CRC patients 
Tumour and PHINOM
i
 
Deregulation of various 
biochemical processes 
Ong  
(2010)
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GC/MS 
LC/MS/MS 
26 patients 
Tumour and PHINOM 
↑ Lipid and amino-acids  
↓Glucose and inositol 
Chan  
(2009)
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HR-MAS NMR 
GC/MS 
31 CRC patients 
Tumour and PHINOM 
↑ tissue hypoxia, glycolysis, 
nucleotide biosynthesis, lipid 
metabolism, inflammation 
and steroid synthesis. 
Hirayama 
(2009) 
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CE-TOFMS 16 CRC patients 
Tumour and PHINOM 
↑ glycolysis, accumulation of 
amino acids , increase in 
TCA cycle intermediaries 
Jordan 
(2009) 
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HR-MAS NMR 5 CRC patients 
Tumour and PHINOM 
None 
Righi  
(2009) 
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HR-MAS NMR 14 CRC patients, 9 
healthy volunteers 
Tumour, HM, PHINOM 
↑Taurine, acetate, lactate, 
lipids increased 
↓Polyols and sugars 
decreased 
Piotto 
(2009) 
104
 
HR-MAS NMR 44 CRC patients
ii
 
Tumour, PHINOM 
 
Denkert 
(2008) 
105
 
GC-TOFMS 30 CRC patients, 9 
healthy volunteers 
Tumour, HM, PHINOM 
↑ urea cycle intermediaries, 
purines, pyrimidines and 
amino acids 
↓ TCA cycle intermediaries 
PLASMA 
Miyagi 
(2011) 
106
 
HPLC-ESI-MS 200 patients, 995 healthy 
volunteers 
↓amino-acids 
Qiu 
(2009) 
107
 
GC-TOFMS 
UPLC-QTOFMS 
64 CRC patients, 65 
healthy volunteers 
↑anaerobic metabolism 
↓amino-acids 
Ikeda 
(2011) 
108
 
GC/MS 12 CRC patients, 12 
healthy volunteers 
↑alanine, proline, glutamine 
and TCA cycle intermediaries 
↓glucuronoic lactone 
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Ludwig 
(2009) 
109
 
NMR 38 CRC patients, 19 
healthy volunteers 
↑ketone bodies, pyruvate and 
lactate 
Ritchie 
(2009) 
110
 
FTICR-MS 
TQ-MRM 
132 sample training set
ii
 
222 sample test set 
↓hPULCFAs 
Ma 
(2010) 
111
 
GC-MS 30 CRC patients, pre and 
post-operative samples 
↓valine, 4-oxo-proline, 
deoxyglucose, turanose, 
maltose, arachidonic acid 
↑tyrosine 
Farshidfar 
(2012) 
112
 
1H NMR 
 
103 pre-operative CRC 
patients with different 
stage disease 
Accelerated glutamine, 
glutamate and galactose 
metabolism in liver 
metastases 
Bertini 
(2012) 
113
 
1H NMR 108 patients with 
metastatic CRC divided 
into long and short overall 
survivors 
↑glycoprotein 
↓creatine, lipid and valine in 
short overall survivors 
 
Backshall 
(2011) 
114
 
1H NMR 54 patients with advanced 
CRC undergoing 
neoadjuvant capecitabine 
chemotherapy 
Toxicity assessed 
↑LDL-like lipid particles in 
patients with severe toxity 
URINE 
Ma 
(2008) 
115
 
UPLC/TOF-MS 24 CRC patients pre and 
post-operative.  9 healthy 
volunteers. 
Class separation observed in 
scores plots of PLS-DA 
models 
Qiu 
(2010) 
116
 
GC-MS 60 CRC patients pre and 
post-operative.  63 healthy 
volunteers 
↓TCA cycle 
↑tryptophan, glutamate and 
gut flora metabolism 
Cheng 
(2011) 
117
 
GC-TOFMS 
UPLC-QTOFMS 
101 CRC patient pre and 
post-operative, 103 
healthy controls
ii
 
↓TCA cycle 
↑tryptophan, glutamate and 
gut flora metabolism 
Silva 
(2011) 
118
 
GC-MS 12 CRC patients, 21 
healthy controls.  Also 
included haematological 
cancer patients. 
Clear class separation in 
unsupervised PCA between 
cancer types and cancer vs 
control. 
FAECAL WATER 
Bezabeh 1H NMR 111 CRC patients, 412 Not stated 
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(2009) 
119
 healthy controls.  Divided 
into training and 
validation sets. 
Monleón 
(2009) 
120
 
1H NMR 21 CRC patients, 11 
healthy controls 
↑leucine, proline, cysteine 
↓butyrate, acetate 
Table 1.6 - Metabonomic based studies on colorectal cancer 
                                                 
i
 PHINOM - Proximal Histologically Normal Mucosa from Cancer Patients 
ii
 These studies validated their training sample set with a separate external validation sample set. 
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1.3.1 Tissue Studies 
Cancerous tissue has been consistently demonstrated to have a distinct metabolite profile to 
normal tissue when investigated with chromatographic and NMR based platforms.  Several 
investigators have used a variety of multivariate statistical techniques to discriminate between 
tissue types and all have been able to differentiate CRC tissue from normal mucosa (Table 
1.6).  Most studies have attempted to generate predictive models for cancerous tissue with the 
exception of Hirayama.
101
  Although the modelling strategies used vary both in their 
methodology and robustness of validation techniques, all have generated models predictive of 
cancerous tissue.   
Chan et al went further and attempted to use OPLSDA modelling to generate models 
predictive of clinico-pathological features.
100
  They were able to discriminate between 
anatomical site of the tumour specimen after excluding the normal samples and reported a 
model with 100% predictive accuracy when using cross-validated predicted Y scores.  
Caution is needed with this finding however as the authors utilised a full, unreduced data set 
to construct this model, unlike that used to generate the model differentiating tumour from 
normal tissue;  consequently even with cross-validation it is more likely to be over-fitted as 
no external validation data set was used to verify the model.   
The possibility to generate models predictive of clinical stage from a small tissue biopsy 
offers a real translatable research benefit for this science but no group has yet achieved this.  
Chan attempted to use Dukes’ stage as a classifier but was unable to generate any valid 
model
100
 and similar results were observed by Ong
99
 although both used relatively small 
sample sets.  Although not generating models predictive of stage, Ong’s sample set included 
patients with benign colonic polyps.  A supervised OPLS-DA model showed class separation 
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between normal tissue, polyp and malignant although the author does not quote any model 
statistics or explore this finding any further.
99
    
Denkert et al. published the first study attempting to differentiate cancerous samples from 
normal tissue; the latter comprised samples from a healthy control group as well as proximal 
normal tissue from patients with CRC.
105
  Utilising a GC–MS approach, he identified a panel 
of metabolites that could differentiate CRC from normal mucosa although unfortunately did 
not attempt to separate these into healthy control and PHINOM.  In unsupervised PCA he 
observed a distinct separation between tissue type and went on to develop well validated 
supervised models able to discriminate between the tissue types.  These yielded 82 
metabolites significantly changed in the cancerous tissue although these were unable to 
absolutely discriminate between tissue types in unsupervised cluster analysis.  Metabolites 
were then classified to a number of different pathways   utilising pathway information from 
the KEGG database.  The author highlights the difficulty in drawing definitive conclusions 
from a dataset that contains incomplete pathway information and makes and confines his 
conclusions to a discussion of changes in pathway groups many of which he ascribes to 
metabolic dysregulation.   
One of the most consistent findings in metabonomic studies on CRC tissue is a relative 
decrease in glucose and increase in lactate in malignant tissue.
98,99, 100, 101, 103
  This 
phenomenon is attributed to the Warburg effect – the production of energy by anaerobic 
metabolism known to occur in cancer cells.  Other observations thought to be consistent with 
this phenomenon such as increased levels of glycine have also been found.
100
   
Denkert observed that certain TCA cycle intermediaries are found at lower levels in 
cancerous tissue and this finding has been repeated by others.
98
  He attributes this to the 
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Warburg effect but opposing findings however were observed by Hirayama.
101
  Utilising CE-
TOFMS, he observed a signficiant increase in succinate, fumarate and malate whilst 
describing a significant decrease in citrate and Cis-aconitate.  He offers the theory that 
succinate, fumarate and malate accumulate as a result of fumarate rather than oxygen is 
utilised as an electron acceptor – a phenomenon observed in certain bacteria.121  Whilst this 
may be a plausible explanation, nonetheless the opposing findings under similar experimental 
conditions highlight the inherent difficulty in drawing conclusions about metabolic pathways 
in the absence of complete metabolic data.   
Amino-acids are readily detected by most metabonomic platforms and many authors have 
documented increases in CRC and measurement of amino acid ratios has highlighted some 
interesting theories about pathway activity in certain cases.  Denkert found a significant 
increase in the glutamate/glutamine ratio in CRC and hypothesized that this may be due to a 
down regulation of glutamine aminotransferase.  Mal et al observed the most significantly 
increased amino acid to be glycine and drew attention to its role in nucleotide synthesis.  
Elevated nucleotides have also been observed with some consistency and their presence along 
with increased levels of free amino acids is consistent with the catabolic state of cancer cells.   
A consistent amino-acid phenotype has not emerged through these studies. 
A fascinating case report by Piotto et al provides an insight into the translatable benefits for 
this research.
122
  Intra-operative samples of colorectal tissue were taken during the resection 
of a tumour.  Samples were blindly analysed by a previously constructed discriminatory 
model
104
 and 8 of the 9 samples correctly assigned to tumour or normal tissue.  Whilst this 
may not yet be as effective as traditional frozen section, the proof of concept principle 
demonstrates potential applications for this technology.  
 
51 
 
1.3.2 Serum Studies 
Blood serum provides a readily available source of metabonomic information for CRC 
patients.  Less invasive than tissue samples, it may provide discriminatory information and 
prove a route to biomarker discovery for a variety of outcomes in the disease.  At the most 
basic level, confirmation of the presence or absence of disease from current plasma 
biomarkers is still poor – sensitivity of serum CEA is about 40% with a 90% specificity123 
when used as a diagnostic biomarker.  As peripherally sampled serum clearly lies further 
downstream to tissue sampling however, it is a reflection of a much wider range of 
physiological processes occurring in the host than just the cancer itself and as a result, 
interpretation of data can be more challenging.  Furthermore, experimental design can have a 
profound effect on the results obtained, well demonstrated by Ma et al who compared blood 
in pre-and post-operative patients undergoing CRC resection.
111
  In this study, the authors 
sampled serum in patients 2 days prior to undergoing surgery and compared it with serum 
drawn 2 hours post-operatively.  Clearly, although the presence and absence of a tumour was 
investigated, the timing of their sample selection introduced a number of potentially 
significant confounding variables.  It is unsurprising therefore that whilst demonstrating a 
clear difference between the groups, the metabolic changes they observed could easily be 
explained by starvation; in the absence of an appropriate control group, further interpretation 
of the results could be meaningless.  A more useful study would follow a cohort such as this 
post-operatively through their follow up and correlate the metabonomic findings with the 
patients clinical course e.g. disease relapse.   
A more useful study design is to compare a group of pre-operative CRC patients with a group 
of healthy controls and utilising this approach a number of authors have been able to 
demonstrate separation of groups and predictive ability in multivariate models.
106-110
  Some 
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authors have made significant attempts to standardise sample collection and carefully match 
their control groups; Qiu carefully excluded all patients with any form of gastrointestinal 
disorder and ensured that all samples were taken fasted, at the same time of day.
107
  This 
approach may be useful when utilising metabonomics to define and describe metabolic 
changes occurring in the disease state but Ludwig et al argued that to discover a useul 
biomarker, sampling typical of clinical practice was more appropriate and consequently 
included all patients attending a rapid access suspected CRC clinic.  Samples were taken at 
different times of day and the control group included patients who were symptomatic from 
some form of gastrointestinal disturbance.
109
  Nonetheless, both investigators demonstrated 
clear differences between classes.   
Whether or not the predictive ability of the models constructed by the investigators above 
represents the presence of CRC specifically or cancer generally is unknown.  The only author 
to attempt to discriminate with other cancer types compared tissue samples of gastric and 
oesophageal cancer as well as CRC and healthy volunteers.
108
  He observed class separation 
between the cancers and significant differences in certain metabolites but did not go on to 
develop a model that specifically discriminated between cancer types.  Another study looking 
at plasma free amino-acids (PFAA) in CRC detected distinct PFAA profiles for each of 5 
solid cancer types including gastric and CRC but these were generally poor at discriminating 
between cancer types particularly between CRC and gastric cancer.
106
   
Elevated levels of a number of amino acids were a consistent finding in metabonomic studies 
on solid CRC tissue and it might be expected that a consequent reduction in circulating 
amino-acids would be seen in plasma samples.  Miyagi recorded an extensive panel of amino 
acids, nearly all of which were significantly reduced in the serum of patients with CRC.
106
  
While the predictive models were robust and showed good predictive ability the author points 
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out that the models were not validated with an external dataset and the sensitivity and 
specificity for individual amino-acids as detection biomarkers was disappointing.   These 
results are not confirmed by Ikeda who noted a significant increase in glutamine, proline and 
alanine
108
 but have been seen by others.
107
   
An exciting study by Ritchie et al utilised FTICR-MS to identify hitherto uncharacterised 
metabolic biomarkers for CRC.
110
  Most significant in this study is the experimental 
workflow that Ritchie chose.  Unlike the other biomarker discovery projects, the investigators 
utilised separate discovery sample sets and validation sets.  In total, 5 patient sample sets 
were used from the USA and Japan, and the authors point to the benefits of such varied 
population in excluding the effects of diet and other environmental factors on the 
metabolome.  3 data sets comprising a total of 132 patients were utilised to identify 3 putative 
biomarkers.  These were then validated with 2 other data sets containing a total of 122 
patients, none of which had been considered in the discovery phase, yielding diagnostic 
biomarkers with Area Under Receiving Operator Characteristic Curve (AUCs) from 0.85-
0.98.  Utilising an organic extraction technique, the investigators obtained FTICR-MS spectra 
for the samples in their discovery sets.  Each of 3 sets was analysed independently and in 
each, those masses that changed with most statistical significance (in all cases a reduction) in 
CRC tissue were considered.  Where concordance between sample sets was seen those 
masses were further considered as biomarkers.  This technique resulted in the identification 
of 13 potential biomarkers.  Structural analysis of these masses revealed them all to be 
hydroxylated, polyunsaturated ultra long-chain fatty acids and assays developed to measure 
the concentration of them directly in further samples.  Utilising these assays on the separate 
validation set showed significant reduction in the cancerous tissue and ROC analysis yielded 
AUCs of 0.871, 0.876 and 0.866.  No significant difference was observed between disease 
stage. 
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Other pathways that have been observed in serum are an increase in aerobic glycolyisis
106, 107, 
109
 and an increase in TCA cycle intermediaries.
108
 
Whilst the presence or absence of disease may be determined by serum metabolite profiles, 
other clinical biomarkers to stage and prognosticate CRC are sought to aid in the treatment 
planning and management of the disease.  Recent efforts on serum studies have focussed in 
this regard but are often hampered by small sample size and lack of external validation. 
Accurate pre-operative staging in CRC is continually pursued and a single serum study has 
been devoted to this.  Using serum samples from 103 pre-operative patients affected with 
CRC, Farshidfar et al attempted to define a metabolic phenotype for different stages of 
disease.
112
  They divided their patients into those with loco-regional disease, those with 
isolated liver metastases and those with extra-hepatic metastases.  Using 1H NMR and GC-
MS, they were able to distinguish between locoregional disease and isolated liver metastases 
as well as between isolated liver metastases and extra-hepatic metastatic disease.  They 
utilised an OPLS-DA model of a panel of metabolite concentrations identified and 
subsequently constructed ROC curves to determine the predictive ability of the models.  GC-
MS gave better predictive models than the NMR data, attributed by the authors to the greater 
number of metabolites detected.  The authors highlighted the statistical significance of their 
modelling measured by CV-ANOVA as well as the relatively high cross-validated Q2 scores 
for the models but did not validate the model with an external validation data set.  An 
interesting question raised in the study is whether the distinct metabolic profile observed in 
patients with liver metastases is a result of the host response to disease involving that organ 
or is a reflection of differences in tumour biology at different stages.  They observed that 
galactose metabolism was accelerated in liver metastases patients, a phenomenon not 
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described in tumour cells.  In addition accelerated glutamine and glutamate metabolism was 
observed, a process known to occur in the liver.   
Bertini et al investigated whether overall survival could be predicted with 1H-NMR analysis 
of serum samples from 153 patients with metastatic CRC.
113
  Utilising a training set, he 
constructed a PLS model capable of discriminating long from short overall survival in this 
group by taking the extremes of survival (10 from each) as classifiers.  Lower levels of 
creatine, lipid and valine were found in short overall survivors along with higher levels of 
glycoprotein.  The model demonstrated an accuracy of 86% when assessed against the 
training set.  To externally validate the model, the author utilised a further set of patient 
samples from another institution and attempted to classify these into short or long term 
survivors based on the previous model and constructed two separate survival curves based on 
these classifiers.  Hazard analysis demonstrated a significant high hazard ratio of 3.37 for the 
predicted short term survivors.  Whilst these results are impressive, particularly given the 
strength of external validation, the metabolic phenotype and differences between survival 
groups may more represent the patient’s current state rather than true prognosis.   Any 
clinician working in oncological practice will recognise those patients whom he expects to 
have a poor overall prognosis without a comprehensive knowledge of their metabolic profile; 
it is perhaps unsurprising therefore that significant differences were observed between the 
two groups for body weight and performance status.  More relevant would have been to 
attempt to prognosticate based on serum samples taken at the time of diagnosis rather than so 
late in the disease process.   
By utilising pre-treatment serum samples, Backshall et al attempted to define a genuinely 
predictive model of toxicity in patients with advanced CRC undergoing neoadjuvant 
Capecitabine chemotherapy.
114
  65 patients with locally advanced and metastatic CRC were 
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included and serum samples taken prior to the commencement of treatment.  Although unable 
to generate a statistically significant discriminatory model, the authors identified four  
spectral resonances discriminating patients with the most extreme drug toxicity including 
polyunsaturated fatty acids and choline phospholipids.  Intermediate drug toxicity lay in 
between.  Aware that these lipid resonances may be related to anthropometric measurements 
known to be correlated with toxicity from other drugs, Backshall assessed the correlation 
between these and the toxicity in her patients.  Whilst baseline weight was negatively 
associated with toxicity it showed no consistent correlation with the lipid resonances under 
investigation. The authors therefore concluded that their markers went beyond a surrogate 
measurement of baseline anthropometric parameters.   
1.3.3 Urine Studies 
Just as serum provides a metabolite rich source of information about the host, the same is true 
of urine which may offer more potential for biomarker discovery given the non-invasive 
nature of its collection.  Also like serum however, the metabolite profile will represent 
biological information about the entire host and their interaction with the environment which 
again provides a challenge for interpreting information about a disease process which may be 
some way from the glomerulus. 
Ma et al published a study similar to the one described previously looking at pre and post-
operative serum samples on patients undergoing CRC resection.
115
  The inclusion criteria and 
sample collection is similar and presumably there is some overlap in the sample populations.  
This time he includes 9 healthy volunteers as a control group.  Again using UPLC-MS he 
reports significant differences in the 3 groups using PLS-DA analysis but this appears to be 
based on the visual inspection of a scores plot derived from the model and no model 
validation statistics are presented.  2 molecular weights are reported to have decreased 
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significantly following surgery but given the number of molecular weights yielded from 
UPLC-MS, this may be the result of over-testing.  In the absence of external validation 
therefore, the results of this study must be interpreted cautiously.   
2 studies from the same group offer the most significant potential for the diagnosis of CRC 
using urine samples.  In the first,  Qiu et al used GC-MS based urinary metabolite profiling to 
discriminate patients with CRC from healthy controls.  Using the same patient set as in their 
previous study
107
 urine samples were collected pre and post-operatively from patients 
undergoing CRC resection as well as healthy controls.  It is unclear from their methodology 
whether the pre-operative samples were taken before or after the administration of bowel 
preparation.  OPLS-DA analysis developed predictive models for the presence or absence of 
CRC and was sensitive to early stage cancers identifying lower levels of TCA cycle 
intermediaries and higher levels of glutamate and metabolites involved in gut flora 
metabolism in patients with CRC.  The latter changes they attribute to a modulated gut micro-
flora associated with CRC although this may be confounded if the CRC patients received 
chemical bowel preparation prior to sampling.  Some of the metabolites associated with gut 
flora metabolism showed a tendency towards the healthy state when measured in post-
operative patients.  No separation was observed between stages of disease or when stratified 
by CEA measurement.   
In a further study, the investigators utilised samples from 101 patients and 103 controls 
divided at the outset into a training and validation set.
117
  Using GC-TOFMS and UPLC-
WTOFMS discriminatory models were developed that revealed a similar panel of 
discriminating metabolites as previously the seven most significant being combined with 
logistic regression into a multivariable.  This multivariable yielded an AUC of 0.998 when a 
58 
 
ROC curve for the test set was constructed.  Again, no differences were observed in tumour 
stage.   
Clearly to be useful clinically, a diagnostic biomarker must be able to discriminate between 
other types of cancer and indeed other potential disease states.  To that effect, healthy 
volunteers may not provide a useful control group.  In a small study looking at CRC along 
with leukaemia and lymphoma patients, Silva et al compared the urinary metabolite profiles 
generated by GC-MS.  In the first 2 components of an unsupervised PCA, there was clear 
class separation between the 4 groups when a panel of 16 metabolites with significant 
differences between groups were used in its construction.  Whilst it is exciting to see such 
results in an unsupervised analysis, the authors provided little information about their patient 
selection.  It is unknown what stage or grade each of cancer each group represented nor is it 
clear which if any were undergoing treatment.  Without this knowledge it may be that these 
results represent something as simple as the urinary excretion of different chemotherapeutic 
regimens.   
1.3.4 Faecal Water Studies 
The close contact between stool and the bowel wall or indeed tumour makes it an obvious 
target for metabolic profiling and biomarker discovery.  Despite reservations about the 
patient acceptance of such tests, it again offers the opportunity for a non-invasive test.  
Additionally, given the associate between gut flora and CRC it may prove useful in 
developing pre-disease based biomarkers of risk for its subsequent development.  Only 2 
studies however to date have attempted to look at this, with mixed results.  In the largest of 
these studies, Bezabeh et al used a training set to develop a series of classifiers discriminating 
between CRC patients and healthy controls.
119
  When tested on a validation set of 56 patients, 
the classifier demonstrated a sensitivity and specificity of 85% and 87% respectively in 
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correctly identifying patients with CRC.  In an earlier study with fewer patients, Monleón’s 
group had demonstrated class separation between CRC and control patients using 
unsupervised PCA as a result of significantly elevated proline and cysteine levels in cancer 
patients along with significant reductions in butyrate and acetate.  Neither of the groups 
attempted to classify patients by other clinicopathological features.  In particular, it would 
have been interesting to note whether any differences were observed by site of tumour as it is 
know that different areas of the bowel contain different floral species.
124
  
1.3.5 Summary 
The past decade have seen a significant interest in the role of metabonomics in colorectal 
cancer.  Broadly, studies have focussed on two areas – furthering understanding of the 
disease and the development of metabolic biomarkers to aid in the diagnosis and management 
of the disease, but have been of mixed quality. 
As with any experiment, study design plays a key role and metabonomics is particularly 
sensitive to even small changes in the experimental protocol or conduct.  Whilst almost 
limitless efforts can be made to standardise sample collection for example, it should be born 
in mind that the ultimate goal of this work, particularly in the case of biomarker discovery, is 
to develop robust and stable biomarkers for use in clinical practice. To this end, provided the 
limitations and design of the experiment is clearly outlined, absolute standardisation may not 
be necessary as demonstrated by Ludwig and colleagues in their experiment on plasma 
samples.
109
 
Interpreting the metabolic information gleaned from this research is complex, particularly in 
those experiments that investigate the biofluids that are inherently downstream of the disease.  
The number of other host and environmental factors in these patients means that the 
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metabolome can easily be perturbed by a process other than the one under investigation.  A 
further problem is found in attempting to draw conclusions about metabolic processes when 
only a fragement of information is available.  Whilst chromatographic methods increase the 
number of metabolites detected, it is by no means complete and the absence or low level of a 
substance can be due either to its true absence or a lack of sensitivity in the chosen detection 
method.  Incorporating a technique-based ‘standard’ into experiments would mitigate this.   
Like other –omics sciences,  there are limitations to what conclusions can be drawn from 
such an incomplete dataset. Considering the example below where ‘B’ is the only metabolite 
or process measured: 
 x  y  
A ⇋ B ⇋ C 
An observed reduction in the concentration of ‘B’ could be due to either a decrease in process 
‘x’, an increase in process ‘y’ or both.  Where the experimental technique does not measure 
metabolites A&B, further information is required to draw any conclusion.  In this case, 
proteomic studies to measure enzymes ‘x’ and ‘y’ could complete the understanding of this 
process but to date, there has been only study has attempted this in CRC.
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Whenever supervised regression analysis is performed there is a tendency for overfitting of 
the resultant model.  PLSDA and OPLSDA are particularly vulnerable to this
126
.  Most 
studies discussed in this chapter have utilised these analytical techniques and have validated 
their results by cross-validation and in some cases ANOVA of the cross validated models but 
internal cross validation may be insufficieint.
126
  Presentation of internally validated 
biomarkers by way of impressive ROC curves is unsatisfactory. “The only way of knowing 
for sure how good a model is, is to apply it to new independent samples in a very large, 
informative test set”. 127  Despite this, relatively few studies have been able, or attempted to 
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do this and have published, what are often very convincing results, prior to external 
validation, even when their sample sets appear large enough to have permitted this.  Only 
when this data begins to consistently appear will the case for metabolic biomarkers be more 
convincing.   
Despite the reservations above regarding the current literature there are a number of 
promising themes that are beginning to emerge.  Tissue, plasma, urine and faecal water have 
all demonstrated the ability to predict the presence of CRC.  To date, none of the studies have 
convincingly demonstrated predictive ability for other factors, perhaps most disappointingly 
for pathological information.  Whether this is a function of what have been on the whole 
relatively small sample sets or whether it represents a truism cannot be ascertained with the 
current number of studies.  Of note,  the ability of metabolite profiling to stage cancers has 
been demonstrated in other solid tumours.
128, 129
 
In addition to the potential it displays with regards to developing novel biomarkers, the 
current literature provides some consistent themes regarding the metabolic pathways that are 
altered in CRC.  Increases in anaerobic energy production has already been described in CRC 
but metabonomic studies offer an easier way to confirm and measure the extent of this than 
by other methods.  Information regarding changes to the TCA cycle is inconsistent and 
whether this represents the heterogeneity of tumour samples or an artefact in experimental 
design is yet to be established.  Most convincingly is the increased mobilisation of amino 
acids seen in tumour cells and matched by a reduction in free plasma levels.  Although 
various studies reveal different results, and the data is not yet complete enough to draw 
conclusions about individual amino-acid metabolic pathways in CRC the trend is very clear.   
Hopefully, in the future, a shift from ‘discovery science’ to a more targeted and hypothesis 
driven approach will to aid in the development of clinically relevant translational solutions. 
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2 Outline & Aims of Thesis 
The work outlined in this thesis evaluates whether 1H NMR profiling of in vitro and in vivo 
colorectal cancer and colorectal tissue samples gives insights into the development and 
treatment of colorectal cancer.  There were three aims: 
Aim 1 – to evaluate the metabolic phenotype of colorectal cancer 
1a Does colorectal cancer demonstrate a metabolic phenotype distinct from normal 
tissue? 
1b What are the metabolic characteristics of colorectal cancer tissue? 
 
Aim 2 – to evaluate whether metabonomics can contribute to colorectal cancer staging 
2a Can the metabolic profile of colorectal tissue be used to discriminate between healthy 
and cancerous tissue? 
2b Can the metabolic phenotype differentiate between cancers by pathological stage?  
2c Can the metabolic phenotype differentiate between cancer specimens by nodal status? 
2d Can any putative biomarkers be validated using an external test data set? 
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Aim 3 – to use metabonomics to evaluate the metabolic changes seen in colorectal 
cancer chemoresistance 
3a What metabolic changes are associated with 5FU chemotherapy? 
3b Is FGF induced chemoresistance associated with a distinct metabolic phenotype? 
3c Can metabonomics be used to explain the mechanisms associated with 
chemoresistance? 
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3 Methods 
3.1 Introduction to NMR Based Spectroscopy 
Nuclear Magnetic Resonance Spectroscopy (NMR Spectroscopy) is an analytical chemistry 
technique that exploits the intrinsic electromagnetic properties of atomic nuclei to determine 
molecular structure and composition within a sample.  It is a relatively fast and automated 
process that can therefore be utilised to analyse a large number of samples in a short space of 
time and unlike other spectroscopic methods is non-destructive to the sample being 
investigated.  In addition it provides a complete analysis of the entire spectrum being 
measured.   
The concept NMR spectroscopy was proposed by Pauli in 1924 and later developed by others 
to exploit the property of nuclear spin known to be intrinsic to many atomic nuclei.
130
  He 
theorised that those nuclei that possessed spin would exhibit split energy levels when exposed 
to a magnetic field, and that electromagnetic pulses could induce transitions in these energy 
levels.  As the nuclei returned to their resting state a characteristic signal would be emitted 
that decays over time.  Because the magnetic field of a particular nucleus is influenced by 
other nuclei in close proximity, this property could be utilised to determine the chemical 
environment of the nucleus.    
3.1.1 Nuclear Spin and Magnetic Fields 
The fact that certain atomic nuclei possess a property known as nuclear spin is fundamental 
to the theory of NMR spectroscopy.  All subatomic particles can be imagined to spin on their 
axis and as such have angular momentum. Unlike electrons which have individual spin, 
nuclei behave as a single entity with spin known as ‘I’.  In the atomic nucleus, containing 
protons and neutrons these particles are paired against each other such that if a nucleus 
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contains an equal number of protons and neutrons it will have no overall net spin (I=0).  On 
the other hand if the number of protons and neutrons is not equal there will be a net spin 
effect (I>0).  This net spin effect can either be an integer (e.g. I=1,2,3,4) where the sum 
number of protons and number or neutrons is odd or a half integer (e.g. I= 1/2, 3/2, 5,2) 
where the sum number of protons and neutrons is even.  In order to be detectable by NMR 
the net spin effect (I) must be greater than zero. 
131
   
The spinning nuclei will possess angular momentum (J)  and just as with any spinning mass, 
such as the earth, the spinning nucleus is associated with a magnetic moment () which 
produces magnetic interactions with its environment: 
 = J 
The gyromagnetic ratio () is a constant for each nucleus and therefore those with larger 
gyromagnetic ratios such as 
1
H are more sensitive in NMR experiments.   
When a strong external magnetic field (B0) is applied to a nucleus, the magnetic moment will 
adopt one of a number of orientations with respect to this field.  The number of possible 
orientations is dependent on the net spin of the nucleus (2I+1) and for 
1
H nuclei this is 
therefore 2 possible configurations.  These configurations have differing energy states, a 
lower energy state (the  state) aligning against the magnetic field and a higher state (the  
state) aligning with the magnetic field in much the same way as when two bar magnets are 
aligned with the poles adjacent or opposite to each other (Figure 3.1). 
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Figure 3.1 – The energy states of a magnetic moment from a 1H nucleus 
When a strong magnetic field is applied to a 
1
Nucleus it will adopt one of two energy states.  
ɯ is the angular velocity of the nucleus and is analogous to the Larmor frequency.  
 
 
The difference in energy states (E ) is defined by the Boltzmann distribution: 
N/N = eE/RT 
Where R is the gas constant and T the temperature in Kelvin.  The frequency of 
electromagnetic radiation required to excite a nucleus into the higher energy state is 
dependent on E and is known as the Larmor frequency (v).  When nuclei are irradiated at 
the Larmour frequency, nuclei alternate between the energy states and are ‘in resonance’ with 
the applied nuclear magnetic radiation.   
During NMR experiments, the specimen under investigation sits within a coil that generates a 
powerful magnetic field (B0) such that the magnetic moments will be aligned in one of the 
configurations previously described.  In fact, the cumulative magnetic moment can be 
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measured as the sum of the individual magnetic moments and represented as a vector known 
as the bulk magnetisation vector.  Whilst the individual magnetic moments are precessing in 
a plane perpendicular to the B0, at the larmour frequency, the magnetisation vector is static 
and as a result no signal will be detected by the receiver coil. When an external 
electromagnetic pulse is applied at 90
0
 to the bulk magnetisation vector, the individual 
magnetic moments, and the overall bulk vector are flipped into a plane perpendicular to the 
original.  The magnetic moments and therefore the bulk magnetic vector continue to precess 
in a plane perpendicular to B0 at the larmour frequency and therefore give rise to a sinusoidal 
electromagnetic signal with a frequency of that of the larmour frequency.  This signal can be 
detected by a receiver coil in this plane.  When the external pulse is switched off, the bulk 
vector gradually returns to its resting state so the electromagnetic signal gradually decays.
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Figure 3.2 – The effect of a 90° pulse on the magnetisation vector of a sample 
When placed in an external magnetic field (B0), the individual magnetic moments of a 
1
H 
nucleus adopt one of two configurations.  Within these configurations, the moments precess 
around in a plane perpendicular to (B0) but the bulk magnetisation vector (Mz) is static and no 
signal detected by the receiver coil (a).  When an external electromagnetic pulse is applied 
the magnetisation vector flips into a perpendicular plane (Mxy) and precesses around it at the 
larmour frequency giving rise to a sinusoidal signal (b).  When the electromagnetic pulse is 
switched off, the magnetisation vector gradually returns to its original configuration and as a 
consequence the component of that vector detectable by the receiver coil gradually 
diminishes (c) until it is zero (d). 
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The decay of the signal is known as the free induction decay (FID), a waveform of decreasing 
amplitude. It is the FID that is characteristic to the metabolite.  Because the other atomic 
particles surrounding any particular nucleus are also affected by the application of a magnetic 
field, the field generated by that nucleus is somewhat ‘shielded’ from that external field (B0).  
For this reason, different 
1
H nuclei will decay at different rates dependent on their 
surrounding environment.   The FID can be subject to a mathematical function known as a 
Fourier transformation in order to give a frequency spectrum measured in hertz.   If a nucleus 
is highly shielded it will tend to have a low frequency whereas conversely, those that are less 
shielded will have a high frequency.  This frequency is known as the ‘chemical shift‘ (δ) as it 
depends on the local chemical environment.  It is not measured absolutely but relative to a 
fixed concentration of a known standard, commonly trimethylsilylproprionate (TSP) in parts 
per million which can then be used to quantify the relative number of nuclei in a chemical 
environment. 
Adjacent atoms in a molecule give rise to fine structure signals as a result of magnetic 
interactions between them known as spin-spin couplings.  As a result of these couplings the 
NMR resonance may be split into separate peaks known as a multiplet depending on the 
number of adjacent hydrogen nuclei.  These characteristic multiplets and their chemical shifts 
can then be used to identify various peaks on the spectrum (Figure 3.3).   
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Figure 3.3 – An illustrative 1H NMR spectrum 
This illustrative 1H NMR spectrum shows a number of resonances.  When the resolution is 
increased distinct multiplets can be seen at particular chemical shifts that represent certain 
metabolites.   
3.1.2 Magic Angle Spinning 
Magic angle spinning is a non-destructive NMR technique that can be used to examine solid 
state specimens.  A small specimen is placed within a rotor that spins at high frequency 
within the magnetic field, lying at the ‘magic angle’ to that field.  At this angle the 
interactions between magnetic moments average zero.  Ultimately, this has the effect of 
narrowing the peaks of the spectra allowing for higher resolution and better analysis and 
identification of the spectrum.
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3.2 Introduction to Megavariate Data Analysis 
By its nature, the dataset acquired from the spectra contains an enormous number of variables 
(>10,000) for relatively few observations.   Classical statistical methodology would involve 
the comparison of one or a few variables at a time across observation groups e.g. Tumour or 
normal tissue.  Whilst this can provide useful information, the comparison of thousands of 
observations individually would clearly be enormously time consuming and lead to statistical 
error.  Extraction of relevant observations for comparison would require a priori knowledge 
of which of the observations were relevant and although some of this information may be 
available in the literature the purpose of this thesis is to attempt to extract new information.  
Consequently, novel statistical methods must be employed in order to mine relevant 
information for further detailed analysis and identify latent patterns amongst the observations 
and variables within the dataset.  Whilst simple univariate or bivariate data can easily be 
represented graphically in two or three dimensions respectively, where the number of 
variables (or dimensions) exceeds two it becomes impossible to represent the relationship 
between them in a graphical form. 
3.2.1 Variable Redundancy 
Principle component analysis attempts to resolve this problem by reducing the number of 
observed variables to a smaller number of unobserved (latent) variables which account for the 
variation seen in the dataset.  These latent variables are known as principle components.  It is 
a particularly useful technique for datasets that contain a high degree of redundancy.  
Redundancy within a dataset refers to the extent to which variables are correlated because 
they are measuring the same thing.  In the case of NMR spectra, redundancy may be observed 
for a number of different reasons, for example due to the significant amount of baseline data, 
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because several peaks correspond to the same metabolite or because 2 or more metabolites 
demonstrate a close relationship biologically regardless of condition.     
3.2.2 Principal Component Analysis 
Principal component analysis is a method of data reduction.  A principal component is 
defined as a linear combination of optimally-weighted observed variables.  It is a 
mathematical construct that defines the maximal total variance within the data.  Represented 
graphically, it draws a line through the data that has the minimal possible distance to all the 
data points using a sum of squares technique much like a correlation coefficient in 
considering the correlation between 2 variables.  
The first principal component calculated in a model will represent the maximal amount of 
variance seen within the dataset.  The second principle component is calculated orthogonally 
to the first such that it accounts for the maximal amount of residual variance i.e. the variance 
not accounted for in the first component.  Graphically, the line is perpendicular to the first 
component.  This process continues until all of the variance within a dataset is accounted for.   
The total variance within a dataset is calculated as the sum of squares (SS) of the distances 
from each data point to its mean in multidimensional space.  The extent to which a particular 
principal component accounts for the total variance seen within a dataset is measured as a 
percentage of this and represented by R
2
X.  It will decrease as each subsequent principal 
component accounts for less and less of the dataset’s variance.  The total variance of the 
dataset accounted for by the model is represented by R
2
X(cumulative), and is simply the sum 
of the individual R
2
X for each component and is a representation of how well the model fits 
the data.  
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Principle components therefore, represent new latent variables that can be thought of as a 
mathematical summary of the measured variables in the dataset.  They are calculated in such 
a way that the 1
st
 and higher order principle components will always account for most of 
variability within the dataset.  
Theoretically, the number of principle components could equal the number of variables.  In 
reality however, the redundancy within the dataset means that much fewer principle 
components are relevant.  Furthermore, as each subsequent component will represent less 
variance than the last, the majority of variance is usually represented within the first few 
components.     
Figure 3.4 illustrates the theoretical basis of principal component analysis using a 3 
dimensional dataset.  Whilst it is impossible to represent more than 3 dimensions of variables 
(or principle components) graphically, higher dimensionalities can be calculated 
mathematically in exactly the same way using multi-dimensional matrices.   
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Figure 3.4 – Theoretical basis of principal component analysis – the Scores Plot 
A dataset with 3 variables – x, y and z is plotted onto a 3-dimensional scatterplot to form a 
‘cloud’ of data points (a).  The 1st principal component accounts for the largest amount of 
fariance seen in the dataset and is represented a line drawn through the data cloud (b).  The 
subsequent principal component (c) is calculated orthogonally (perpendicular) to the previous 
component and passes through the datacloud in whichever direction accounts for majority of 
the residual variance.  The distance from each component (illustrated by yellow datapoint) is 
squared and summed to give the total variance accounted for by that component (R
2
X).  The 
data cloud can be projected onto a new 2-dimensional axis (d). 
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Scores represent the value of an observation with respect to a particular principle component 
or newly defined latent variable as seen in Figure 3.4d.  Consequently, observations that have 
underlying similarities will tend to cluster together when placed on a new plot where the 
principle components now represent the new axes.  These groupings may be missed if the 
same observations are plotted on 2 of the original variables.  Equally, it may be necessary to 
examine a number of different lower order components to find those that account for the 
differences between the groupings that are under investigation. 
The loadings represent the extent to which the original variables contribute to principle 
components.  They are calculated by taking the cosine of the angle the principle component 
makes with a given variable (Figure 3.5).  Therefore when variables are plotted with two 
principle components as their axis the variables will cluster based on how related they are.  
Variables that are strongly correlated will cluster together and those that are inversely related 
will appear in opposite quadrants.  The distance of the variable from the origin increases with 
extent to which that particular variable contributes to that component.     
76 
 
 
Figure 3.5 – Theoretical basis of principal component analysis – the Loadings Plot 
The same 3 variable dataset as in the previous figure is shown with the first 2 principal 
components overlaid (a).  The ‘loading’ of each variable is a measure of to what extent it 
contributes to each principal component and is calculated by taking the cosine of the angle 
between the principal component and the variable axis (b).  ‘z’ makes a strong contribution 
towards PC1 and the ‘y’ variable towards PC2.  ‘x’ does not contribute significantly towards 
either component and therefore has more ‘redundancy’.   
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3.2.3 The effect of Scaling 
PCA is calculated by sequential determination of the maximum variance within the dataset; 
therefore if the data is not scaled (weighted) those variables within the data that have a large 
range and hence large variance are more likely to be expressed in the models created than 
those with a smaller range.  This is advantageous when all of the variables in the dataset are 
measured in the same way, and therefore the different variable ranges are due to true 
biological events.   
The NMR spectra obtained however, in particular of the tissue and cell extracts, a number of 
metabolites were detected in the aromatic region of the spectra at significantly lower 
concentration than those seen in the aliphatic region.  PCA performed without scaling would 
result in changes in these low concentration metabolites being underrepresented in the final 
model and therefore scaling techniques were applied to the dataset before analysis.   
Effectively, scaling has the effect of equalising the length of each variables coordinate axis.   
2 forms of scaling were employed.  Unit Variance scaling, where each datapoint was 
weighted by the inverse standard deviation of that variable resulting in all variables having a 
variance of 1.  Parieto scaling was also employed which weighs each datapoint to the inverse 
of the standard deviation of that variable.  The latter therefore is a middle ground between 
full UV scaling and no scaling.  
3.2.4 Data Centring 
Data is centred about the average value for each variable before analysis.  By doing this, all 
variables are centred around zero as are the subsequently calculated principle components.   
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3.2.5 Outliers, DModX and Hotelling 
An outlier can exist due to biological diversity or experimental error.  Their identification and 
appropriate treatment of them is essential for developing robust PCA models.  A strong 
outlier will appear on plots of PCA scores and its inclusion in the analysis can have a 
tendency to dominate a particular principle component.   A statistical assessment of outliers 
can be made using Hotelling’s T2, which is based on a multivariate Student’s t-test.   An 
alternative facility provided by SIMCA is DModX, a function that calculates how far a 
particular observation lies from a given principle component.   
3.2.6 Model Validation 
R
2
X is a measure of  the extent to which the model fits the data i.e. the percentage of the total 
variance explained by the model. However, it does not characterise the predictive ability of 
the model which must be assessed using some form of validation.   
One method of doing so is by cross validation where the data are divided into parts (in this 
case 7 parts) and each 1/7th in turn is removed. A model is built on the 6/7th data left in and 
the left out data are predicted from the new model.  This is repeated with each 1/7
th
 of the 
data until all the data have been predicted. The predicted data are then compared with the 
original data and the sum of squared errors calculated for the whole dataset.  This is then 
called the Predicted Residual Sum of Squares.  It is represented on a scale of 0-1 as Q
2
 with 0 
representing no predictive ability and 1 representing very high predictive ability. Typical 
values that might be obtained in common PCA applications are given in Table 3.1. 
  
79 
 
Application R2 Q2 
Spectroscopic Calibration 0.99 0.98 
Good QSAR model 0.78 0.65 
Biological PCA model 0.5 0.4 
PCA Stable Process 0.3 0.2 
PCA Market research 0.3 0.2 
Table 3.1 – Typical values obtained in common PCA applications 
(from Multi- and Megavariate Data Analysis, Umetrics Acacdemy, 2006) 
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3.2.7 Partial Least Squares Discriminant Analysis 
Whereas PCA is an unsupervised regression analysis that has no pre-existing knowledge of 
sample classification, Partial Least Squares Discriminant Analysis (PLSDA) is a supervised 
regression technique in which the sample classification is incorporated into the model.  It is a 
variant of partial least squares regression, adapted for correlating categorical variables (Y) 
such as clinical outcome, pathological stage or treatment with continuous biological variables 
(X) such as NMR data.
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 Like PCA, it reduces a series of biological variables to fewer 
number of latent variables and again observations are projected onto these latent variables in 
multidimensional space.  The space is then mathematically rotated, in order to find a plane in 
which maximum class separation occurs and principal components derived in this space 
(Figure 3.6).   
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Figure 3.6 – Theoretical basis of partial least squares discriminant analysis 
As in the previous examples, a dataset with three variables is plotted in 3-dimensional space; 
Class 1 is coloured blue and class 2 is coloured green (a). The space is rotated in order to find 
the maximum separation between classes and principal components derived maximising the 
separation between classes (b).  The observations can then be plotted onto a 2-dimensional 
axis against the principal components of the model.  
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3.2.8 Assessment of Reliability 
Cross-validation only assess the predictive power (Q2Y) but makes no assessment of the 
statistical significance of this predictive power.  CV-ANOVA has been described as a method 
for determining the statistical significance of a model by comparing the size of their fitted 
residuals.
136
  Where PLSDA models are used here, CV-ANOVA is performed to test their 
significance.  
3.3 Collection of Human Tissue Samples 
Samples and clinical data in this study were handled and processed in accordance with the 
local Research Ethics Committee approval (07/H0712/112) which permitted the collecting of 
samples for use in this study as well as the deposit of excess samples in a tissue bank with 
pre-existing ethical approval (06/Q0403/16).  The ethical approval for this study permitted 
the use of the pre-existing samples in the tissue bank for this study.   
Following written consent, samples were collected from 30 patients undergoing elective 
resection of a colorectal cancer at St. Mary’s Hospital between 2007 and 2009.  Cancer 
specimens were taken from the operating theatre to the pathology department on ice where 
they were examined by a histopathologist and sampled. Samples were obtained from the 
macroscopic tumour and an area of proximal normal tissue.  The samples were then snap 
frozen and stored at -80°C prior to analysis.   
3.4 Cell culture 
SW480 are immortalized human colonic adenocarcinoma cells derived from a 51 year old 
male with Dukes B carcinoma, SW620 are a colonic adenocarcinoma cell line isolated from 
the lymph node metastasis of the same patient and both were obtained from the European 
82 
 
Collection of Cell Cultures (ECACC, CAMR, Wiltshire).  Cells were grown in Dulbecco’s 
Modified Essential Medium (DMEM) with GlutaMax supplemented with 10% (v/v) foetal 
calf serum (FCS) (all from Gibco BRL, Life Technologies, Paisley). 
3.4.1 Cell culture conditions, subculture and freeze-thaw 
Cells were maintained in standard humidified conditions (5% CO2, 37°C) and harvested 
when sub-confluent.  Cells in tissue culture flasks were harvested by treatment with 0.25% 
(w/v) trypsin in Dulbeccos phosphate buffered saline (D-PBS; Gibco BRL) following the 
removal of spent culture medium.  Cells were treated with 5 ml of the trypsin solution for 3-5 
mins at 37°C until the cells began to lift off the base of the flask, 5 ml of serum containing 
DMEM (SC-DMEM) was then added and cells and media transferred to a 15 ml centrifuge 
tube and centrifuged at 800 x g for 6 mins at room temperature.  The supernatant was 
discarded and the cell pellet re-suspended in an appropriate volume of media and inoculated 
into culture flasks and allowed to adhere overnight.   
 
Frozen cell stocks were stored at -70C, stocks were thawed at room temperature and 
transferred to a centrifuge tube containing 10 ml of SC-DMEM and cells pelleted by 
centrifugation and the supernatant discarded.  Cells were seeded into 25 cm
2
 tissue culture 
flasks and allowed to adhere in normal fashion. Stocks for storage were frozen as per 
individual suppliers’ cell freezing protocols utilising 10% (v/v) Dimethyl Sulfoxide (DMSO, 
Sigma Chemical Company Ltd., Poole, Dorset) in SC-DMEM. Cell samples were frozen at -
70°C for 24 hours before transfer to liquid nitrogen.  
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3.5 Chemoresistance model 
SW620 and SW480 cells where seeded at a density of 4 – 5 x 105 cells in a 60 mm petri dish 
in a final volume of 3 ml of SC-DMEM and allowed to adhere and proliferate at 37C for 48 
hrs.  Cells where then washed by replacing the SC-DMEM with serum-free DMEM (SF-
DMEM) for a further 24 hrs.  The four treatment conditions comprised cells treated with SF-
DMEM, 0.25 ng/ml of Fgf-2 (R&D systems, Abingdon, Oxfordshire), 50 µM of 5-flurouracil 
(Sigma) or a combination of 0.25 ng/ml of Fgf-2 and 50 µM 5-flurouracil, all prepared in SF-
DMEM.  Cells to be treated with 0.25 ng/ml of Fgf-2 or 0.25 ng/ml of Fgf-2 and 50 µM 5-
flurouracil where first primed by treatment for 4 hrs with 0.25 ng/ml Fgf-2.  Once treated 
cells where incubated for 24, 48, 72 or 96 hrs at 37ºC.  Following treatment  the culture 
supernatant was removed to a fresh container and cells washed in 1 ml of D-PBS, harvested 
by cell scraping, transferred to a 1.5 ml microfuge tube and centrifuged for 6 mins at 652 x g 
and the PBS-supernatant discarded, both culture supernatant and cell pellets where then 
stored at -70ºC until further analysis. 
3.6 Sample Preparation for NMR Spectroscopy 
3.6.1 Preparation of Whole Tissue for 1HNMR Magic Angle Spinning 
Samples were transported to the  NMR suite on dry ice.   After thawing to room temperature 
samples were washed with 200 microliters of 95% D2O for 10 seconds and weighed.  The 
sample was loaded into a zirconium rotor, ready for NMR spectroscopy. 
3.6.2 Preparation of Tissue Extracts for 1H NMR Spectroscopy 
Samples were kept on dry ice throughout the preparation phase.  After removal from the 
freezer approximately 25mg of frozen tissue was dissected from the sample and placed in an 
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eppendorf.  300 μL of a solvent mixture of freshly prepared 1:2 mixture of duterated 
methanol:duterated chloroform was added and the sample manually homogenized using an 
eppendorf micropestle.  300 μL of HPLC grade water  was added to each tube before 
vortexing.   The resulting homogenate was then centrifuged at 16000g for 10 min.   
On removal from the centrifuge the sample separated into an upper aqueous phase and a 
lower organic phase.  The phases were separated using a micropipette and placed in separate 
glass vials.   The process was then repeated on the residual protein pellet to maximise the 
extraction and the resulting phases combined with the 1
st
 aqueous and organic phases.   
Both phases were left in a fume cupboard overnight to evaporate the methanol from both 
phases.  The aqueous phase was then freeze dried to remove residual water and both (now 
dry) phases frozen at -80 until required for further use. 
The aqueous phase was reconstituted in 600μl of phosphate buffer containing 0.002% 3,3,3 
trimethylsilylpropionate (TSP) and 0.02% azide.  This was transferred to an eppendorf and 
centrifuged for 5 minutes at 16000g.  550μl was then pipetted into a labelled NMR tube for 
analysis.   
The organic phase was resuspended in 700μl CDCl3 containing 0.03% TMS before 
transferring to an eppendorf and centrifuging for 5 minutes at 16000g.  600μl was then 
pipetted into a labelled NMR tube for analysis.   
3.6.3 Preparation of Cell Extracts for 1H NMR Spectroscopy 
Cells were similarly extracted by adding 300 μL of methanol-chloroform –before vortexing 
to mix.  A further 300μl of  H2O was added and the mixture vortexed again.  The  resulting 
suspension was then centrifuged at 16 000 g for 10 minutes to separate the mixture into 
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aqueaous and organic phases. The upper aqueous layer was then separated from the lower 
organic layer and the residual methanol allowed to evaporate off overnight in a fume 
cupboard.  Samples were then frozen at -80 before being reconstituted in 600μl of phosphate 
buffer of which 560μl was added to an NMR tube for analysis.   
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3.7 NMR Pulse Sequences 
The characteristics of the pulse sequence used in an NMR experiment control the duration, 
amplitude and number of pulses in the experiment.  Following the pulse the FID is recorded 
as previously described.  Typically, the pulse, FID recording is repeated a number of times 
and the summed FIDs acquired improve resolution.   
Water in the sample under analysis will tend to dominate the signal acquired unless 
supressed.  To do this, a presaturation pulse is given prior to the main acquisition pulse.  This 
presaturation pulse is of low energy and at the exact frequency at which the protons in a 
water molecule precess.  This results in saturation of the water signal, obliterating it from the 
spectrum. 
2 established pulse sequences were used in the analysis of samples in this thesis, both of 
which contained a presaturation pulse.  The 1 dimensional  NOESY pulse sequence consisted 
of the application of three 90° pulses with a water presaturation between each 90° pulse and 
has the advantage of slightly better suppression of the solvent signal but can suffer from 
overlap of larger molecules such as proteins which are detected with this method.  To 
overcome this a CPMG sequence was also used, This consists of an initial 90° pulse followed 
by repeated 180° pulses.  The consequence of this is relative suppression of the larger 
molecules with consequent better resolution of low molecular weight metabolites.
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3.8 Spectral Processing 
A number of different pre-processing steps were applied to the raw NMR data prior to multi-
variate data analysis.  Firstly, raw Fourier Induction Decays were  imported into the Bruker 
NMR processing program ‘TopSpin’ and  Fourier transformed to give a distinct spectrum.   
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The spectra were individually inspected then manually phase and baseline corrected in order 
to convert all spectra to a linear baseline at zero.  This was necessary to perform subsequent 
analysis such as integration of areas under the peaks.  Following this the spectra were aligned 
to the stable reference peak – TSP. 
3.8.1 Normalisation 
Following pre-processing, spectra were imported into MATLAB using in house software, 
MetaSpectra, which was written and compiled in MATLAB by Dr T.M.D. Ebbels, Dr. H C. 
Keun, Mr J.T.Pearce, Dr Rachel Cavill & Dr. Olivier Cloarec.  
Because variation in the spectra will exist due to the absolute (rather than relative) metabolite 
concentration in each sample (for example due to a slightly more effective extraction), 
spectra must be normalised in order to make comparisons between them.  A number of 
different normalisation strategies exist, in this case normalisation was to median fold change.  
Here, a median spectra is calculated for the dataset and each individual spectra divided by 
this to give a fold change for each point on the spectra. 
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3.8.2 Data Reduction 
In order to reduce the volume of data derived from the NMR spectra, the spectral resolution 
was reduced to a resolution of 0.005ppm by taking selective ‘bins’ of the data at these 
distances.  The residual water region between 4.5-6.0ppm was removed as with the area 
corresponding to the external TSP reference standard. 
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3.8.3 Integration of peaks 
Metabolite peaks were integrated in order to  compare the relative amounts of metabolites.  
This was performed utilising MATLAB code written by Dr Rachel Cavill and Dr Hector 
Keun.  
3.8.4 Statistical Analysis 
This processed and integrated data was then imported into statistical software packages for 
analysis.  SPSS was utilised for comparison of individual metabolites between sample classes 
which were compared using a t-test with Welch’s correction.  SIMCA was utilised for 
multivariate analysis and pattern recognition techniques as described in section 3.2. 
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4 The Metabolic Phenotype of Colorectal Cancer  
4.1 Introduction 
A number of different tumours have been shown to exhibit a metabolic phenotype distinct 
from the normal healthy tissue from which they arise.  Indeed, metabonomic techniques have 
been used successfully used to identify and characterise these differences in several different 
tumour types and could provide the basis for the discovery of new biomarkers and therapies.  
Previous studies have examined bowel cancer using MAS mass spectroscopy of whole tissue 
but may fail to identify some very low concentration metabolites. 
The experiments presented in this chapter were designed to examine the differences between 
tumour and normal tissue, determine whether there was a distinct and robust metabolic 
fingerprint associated with colorectal cancer and to characterise the changes seen in tumour 
tissue.   
4.2 Experimental Design 
Samples were collected from patients undergoing elective resection for colorectal cancer.  
Following excision of the bowel, the specimen was conveyed to the pathology department 
where a random sample of tissue was taken from the macroscopic tumour along with a paired 
sample of tissue from the proximal segment of normal bowel.   The remainder of the 
specimen was then subject to normal clinical histopathological investigation.  There was a 
variable time delay between ligation of the mesenteric vessels, excision and sampling due to 
variations in surgical technique.   
Clinical and pathological data was obtained prospectively from the patients notes as well as 
the clinical colorectal cancer database and histopathology reports.     
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Tissue samples were extracted into aqueous and lipid fractions and 1H NMR spectra obtained 
using the methods described in the methods section.  
Spectra were individually inspected and pre-processed as previously described before being 
exported into MATLAB for further data cleaning and analysis.  Spectral peaks were assigned 
using Chenomx software and further validated with reference to published work using similar 
tissue and techniques.   
The full dataset was reduced into ‘buckets’ of 0.005 parts per million and principle 
component analysis performed to determine the difference between the malignant and normal 
tissue.  Analysis of the loadings plots identified those metabolites that contributed most 
significantly to the model in order to define a metabolic fingerprint associated with 
malignancy.   
Integral intensities of each of the metabolites indentified within the metabolic fingerprint 
were calculated using in-house software scripts as described in methods.  The relative 
metabolic intensities were compared and tested for significance in SPSS using one-way 
ANOVA with significance set at <0.05.  
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4.3 Results 
4.3.1 Colorectal Cancer Patient Cohort 
Samples were collected from 26 patients along with complete clinical and pathological data.  
4 further paired samples were available in the pre-existing tumour bank as outlined in the 
Methods section and ethical approval for this study permitted their inclusion;  clinical and 
pathological data was not available for these as the samples had been anonymised prior to 
deposit for another study but as tumour and normal tissue were separately stored these 4 
patients were included in the experiments to distinguish between tumour and normal but not 
by other characteristics.    
A sample of tumour was taken at macroscopic histological examination along with a paired 
sample of macroscopically normal tissue from approximately 5cm upstream.  The details of 
the samples are given in Table 4.1.  6 of the samples were from true rectal cancers and 16 
were intra-peritoneal.  The remaining 4 for which full pathological information was available 
occurred at the recto-sigmoid junction.  The age and sex distribution were as expected and a 
range of histological stages were represented.  All cancers were adenocarcinomas with the 
exception of ‘patient 24’ were the histology revealed a high grade tubullovillous adenoma 
with a small focus of high grade dysplasia.  The sample taken for 
1
H NMR analysis was from 
the adenoma.  Most of the tumour samples were moderately differentiated with the exception 
of three poorly differentiated tumours which appeared to be mucinous.  Further histological 
data available included evidence of perineural invasion, lymphovascular invasion and 
extramural vascular invasion,  all of which are independent markers of prognosis.   
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Patient Age Sex Site Dukes Stage TNM Stage E L P M 
1 53 F Recto-sigmoid C pT3,N2 y y n n 
2 
     
    
3 73 M Sigmoid C pT4,N1 y n n n 
4 84 M Sigmoid A pT3,N0 n n n n 
5 78 M Sigmoid B pT4,N0 n n n y 
6 70 M Sigmoid C pT3,N1 y n n n 
7 57 F Rectum A pT1,N0 n n n n 
8 
     
    
9 85 M Transverse colon B pT4,N0 n n n n 
10 46 M Recto-sigmoid B pT3,N0 y y n n 
11 81 M Recto-sigmoid C pT4,N1 y y n n 
12 40 M Sigmoid C pT4,N2 y n n n 
13 72 F Sigmoid C pT2,N1 n n n n 
14 
     
    
15 24 F Transverse colon C pT3,N1 y y n y 
16 73 M Sigmoid C pT4,N1 y n n n 
17 63 F Hepatic flexure B pT3,N0 n n n n 
18 83 F Ascending colon B pT4,N0 y n n n 
19 70 F Rectum B pT4,N0 n n n n 
20 86 F Rectum B pT3,N0 y n n n 
21 65 F Recto-sigmoid B pT3,N0 n n n n 
22 67 F Rectum C pT3,N1 n n n n 
23 77 F Rectum C pT3,N1 y n n n 
24 74 F Sigmoid C pT4,N1 y n n n 
25 79 F Sigmoid C pT4,N2 y y n n 
26 66 F Caecum C pT2,N1 n n n n 
27 
     
    
28 56 M Transverse colon C pT4,N1 n y n y 
29 77 F Sigmoid B pT4,N0 n n n n 
30 66 F Rectum A pT2,N0 n n n n 
Table 4.1 – Clinical and pathological characteristics of patient samples 
E Extramural vascular invasion  P Perineueral invasion 
L Lymphatic invasion   M Mucinous  
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4.3.2 Spectral Assignments of Colorectal Tissue 
After pre-processing and clean up as described in the methods section, spectra were visually 
inspected.   Metabolites were assigned to spectral resonances by reference to previously 
published data on similar tissue.
100, 139
 reference to the human  metabolome database
140
 well 
as using Chenomix spectral analysis software.
141
   
In order to aid assignment of resonances where the spectral area contained a significant 
amount of overlap of peaks, STOCSY analysis was performed to identify which groups of 
peaks were associated with the same metabolite.  An illustrative example of this is shown in 
Figure 4.1 which demonstrates the STOCSY obtained for the peaks corresponding to the 
driving peak for AXP at δ6.14. 
 
Figure 4.1 – STOCSY Analysis for AXP 
The STOCSY performed on the driving peak at 8.6 revealed several other peaks with strong 
correlatioins at 8.27 and 8.60.  Interrogation of the human metabolome database and 
peakfitting using Chenomx software permitted AXP to be confidently assigned to these 
resonances although it was not possible to further discriminate which nucleotide was present 
 
Figure 4.2 shows median CPMG spectra obtained from NMR analysis of the aqueous fraction 
of tumour and normal tissue. Whilst the intensity scale is given in arbitrary units, those 
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metabolites found in the aliphatic region of the spectra gave significantly stronger signals 
than those found in the aromatic region.   In total, 34 metabolites were confidently assigned 
to 60 resonances (Table 4.2).   
Amino acid resonances predominated and 11 were confidently identified.  In the aromatic 
region of the spectra the signal intensities were much less than in the aliphatic region and as a 
result, identification of peaks more challenging.  A number of nucleobases and their 
nucleotide derivatives appeared to be represented however as a result of significant spectral 
overlap in this region as well as a relatively poor noise to signal ratio in the aromatic region 
meant that they could not always be precisely assigned to the exact derivative but where 
possible the most likely assignment is given. 
The carbohydrate myo-inositol was identified as was glucose, both of which were very varied 
in their signal intensity depending on the sample.  In addition lactate gave a clear and 
consistent doublet at δ1.32 and to a lesser extent a singlet at δ4.11 the former being used to 
standardise the spectra.   
Choline containing compounds gave a clear signal at 3.19-3.22.  Although a number of peaks 
were identified, clearly corresponding to choline, phosphocholine and glycerophosphocholine 
significant overlap of peaks made quantification of these metabolites difficult and as a result 
the peak fitting feature of Chenomx was used to aid quantification. A similar problem was 
encountered in attempting to quantify the creatine and creatine-phosphate peaks at δ3.03 and 
δ.04 respectively.  
95 
 
 
Figure 4.2 – Median CPMG Spectra obtained from all tissue samples 
The Fourier Induction Decays are Fourier Transformed into a spectrum.  Each metabolite 
identified will have 1 or more resonance or chemical shift seen as peaks along the x-axis 
reproducible across experiments.  Identification of these peaks is possible using pre-existing 
databases as outlined in the methods section.    The y-axis has no units but corresponds to 
signal intensity whilst the area under the peak is proportional to the concentration of the 
particular metabolite in the sample.   
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Metabolite δ1H   Metabolite δ1H  
       
Isoleucine 0.93 t  Scylo-inositol 3.34 s 
 1.00 d     
    Glycine 3.56
0 
s 
Leucine 0.95 d     
 0.96 d  PEG 3.70 s 
 1.70 m     
    Glucose 5.23 d 
Lysine 1.72 m     
 1.91 m  Uracil 5.79 d 
     7.54 d 
Valine 0.98 d     
 1.03 d  Uridine 5.91  
     7.87  
3-Hydroxybutyrate 1.19 d     
    GTP 5.94 d 
Lactate 1.32 d     
 4.11   UDP-glucose 5.99  
       
Alanine 1.47 d  Inosine 6.09 d 
 3.78    8.24 s 
     8.34 s 
Glutamate 2.05 m     
 2.13 m  AXP 6.14  
 2.34 m   8.27 s 
 3.76    8.60 s 
       
Glutamine 2.13 m  Fumarate 6.51 s 
 2.44 m     
    Tyrosine 6.90 d 
Aspartate 2.80 dd   7.19 d 
       
Creatine 3.03 s  Phenylalanine 7.34  
 3.92 s   7.38  
     7.43  
Creatine phosphate 3.04 s     
    Pyridoxine 7.67 s 
Choline 3.19 s     
    Hypoxanthine 8.20 d 
Phosphocholine 3.21 s     
    Niacinamide/Niacinurate 7.59  
Glycerophosphocholin
e 
3.22 s   8.71 d 
       
Taurine 3.26 t  Formate 8.45 s 
 3.41 t     
       
Myo-inositol 3.27 t     
 3.53 dd     
 3.62 t     
 4.06 t     
Table 4.2 - Panel of metabolites detected in colorectal tissue samples 
Resonances may occur as a single (s), double (d) or multiple peaks along the spectra.  
Furthermore they may appear as an isolated resonance at only one chemical shift or in several 
places according to their chemical properties.  The characteristic appearance of the peaks 
along with their co-resonances permits identification of the metabolite using existing data.   
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1H NMR Spectroscopy discriminates between tumour and normal tissue 
In order to determine whether there were any differences between tumour and normal tissue, 
unsupervised principle component analysis models were created of the ‘binned data’.  
Although the resulting models were relatively weak (crossvalidation of the model revealed an 
R2X of 0.60 and Q2 of 0.38), clear separation of the tumour and normal tissue could be seen 
when the scores plots were inspected.  Although outliers existed in both tissue types, 
inspection of the spectra and review of the clinical details from these samples revealed no 
clear reason why this should be the case and they were therefore included in further analysis.   
Loadings of the model revealed that the samples clustered largely on the basis of two distinct 
resonances at  1.32 and 3.70 corresponding to lactate and polyethylene glycol (PEG) 
respectively.  As the latter represents an exogenous compound used as bowel preparation 
before colorectal surgery it was excluded from analysis and the models reconstructed (Figure 
4.4).   
 
Figure 4.3 – PCA scores plot of cancer versus normal tissue 
Scores plot of the first two components of an unsupervised PCA model showing the 
difference between tumour and normal tissue after exclusion of the area of the spectra 
representing PEG.  Normal tissue is shown in black and tumour samples in red. R
2
=0.59, 
Q
2
=0.38. 
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After exclusion of PEG, the model was reconstructed and clear class separation along  the 2
nd
 
PC was seen  and to a lesser extent the 1
st
 PC (Figure 4.4).  The loadings plot showed lactate 
dominated the separation in the 1
st
 PC but that a number of other resonances dominated in the 
2
nd
 along which the majority of the class separation was seen. 
 
Figure 4.4 – PCA loadings plot of cancer versus normal tissue 
The loadings plot corresponding to the first 2 components of the PCA model shown in Figure 
4.3.  The unsupervised model separates the cancerous and normal tissue along the second 
component which is dominated by choline containing compounds and taurine.  In 
unsupervised analysis, lactate does not appear to contribute to the class separation. 
 
In an attempt to further define those areas of the spectrum responsible for the separation 
between normal and malignant tissue, an OPLSDA analysis plot was constructed.  This 
generated a robust model with a number of discreet resonances as well as areas of the spectra 
contributing to the difference in tissue types.  A number of metabolites were strongly 
correlated with the malignant tissue type.  All of these had been previously assigned to 
metabolites.  Glutamate (δ2.05, δ2.34) and Taurine (δ 3.26, δ 3.41) were the most strongly 
correlated with the malignant tissue whilst myo-inositol(δ3.57, δ3.62) were most strongly 
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correlated with the normal tissue and dominated the model.  Lactate (δ1.32) did not appear to 
have a strong correlation although was associated with the malignant tissue type (Figure 4.5).    
 
 
Figure 4.5 – OPLSDA coefficients plot of normal and malignant tissue 
OPLSDA coefficient plot of results from 
1
H-NMR analysis of tissue samples taken from 
normal (downwards) and malignant (upwards) tissue.  , R
2
Y=0.57, Q
2
Y=0.39. 
4.3.3 Integral Intensity Changes in the Metabolites Identified 
Using the data from the loadings plots, a panel of metabolites was identified representing 
those which contributed to the model.  In addition those metabolites that could be clearly 
identified from visual inspection of the spectra as having obvious differences between tumour 
and normal were also included.   
Of the 61 resonances that were assigned from the spectra, it was possible to calculate integral 
intensities for  51 of them.  Where there was a significant amount of overlap between 2 or 
more peaks, they were not included.  All of the metabolites identified however were 
represented.  Integral intensities were calculated using in-house software scripts, and were 
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added where 2 or more peaks corresponded to the same metabolite.  Consequently, intensities 
relate only to the change for that particular metabolite between the two groups rather and 
cannot be compared with other metabolites.  An independent t-test with Welch’s correction 
was used to compare intensities of the metabolites. 
4.3.4 Malignant Tissue exhibits increased anaerobic glycolysis 
Glucose levels were significantly reduced in malignant tissue samples to approximately 49% 
of the levels seen in normal tissue (p<0.01).  Lactate levels showed a modest but significant 
increase of 13% in malignant tissue (p<0.05).  A weak positive correlation was observed 
between glucose and lactate in both normal and malignant tissue however this correlation was 
slightly increased (r2=0.066, p<0.170) in malignant tissue compared to normal (r2=0.022, 
p=0.439) (Figure 4.6).   
The two TCA cycle intermediaries characterised in the spectra (fumarate and isocitrate) 
demonstrated opposing fold changes in malignant tissue where fumarate was decreased to 0.7 
of that seen in normal tissue (p<0.05) and isocitrate demonstrating a mild 1.1 fold increase 
that was not statistically significant.   As the TCA cycle intermediaries are produced on a 
1:1:1 basis in aerobic glycolysis, their integral intensities were summed to provide a marker 
of total TCA cycle intermediary present in the sample for comparison with glucose.   
Correlation of glucose with the TCA cycle intermediaries demonstrated a significant positive 
correlation in normal (r2=0.314, p<0.001) but not in malignant tissue (r2=0.048, p=0.24).  
Table 4.3 shows the integral intensities calculated for glucose and its glycolytic metabolites 
identified in the spectra. 
 
101 
 
 (a) (b) 
  
(c) (d) 
  
Figure 4.6 - The Warburg Effect in Malignant Tissue 
All concentrations are presented relative to the mean of normal tissue.  Normal tissue is 
shown in black and malignant tissue in red.  (a) a significant increase was observed in lactate 
in malignant tissue (p<0.01) along with a reduction in glucose concentration (p<0.01).  (b) a 
weak positive correlation was observed between glucose and lactate in both normal 
(r
2
=0.022) and malignant tissue (r
2
=0.066) and although neither correlation  reached 
statistical significance, it approached significance in malignant tissue (p=0.170) compared to 
normal (p=0.439). (c) reduction in fumarate levels in malignant tissue (p<0.05) and no 
significant change seen in isocitrate levels (p=0.194). (d) a strong positive correlation 
observed between glucose and TCA cycle intermediaries in normal tissue (r2=0.314, 
p<0.001) was not present in malignant tissue (r2=0.048, p=0.24) 
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In the absence of corroborating data about protein expression and other intermediate 
metabolites, the ratios of the 3 glycolytic products to glucose were compared between normal 
and malignant tissue as well as ratios of the products to each other as the best available 
surrogate marker of pathway activity (Table 4.3) such that a relative increase in such ratios in 
malignant tissue (compared to normal) can be interpreted as a relative increase in activity of 
this pathway.   
Lactate/glucose ratios were used as a surrogate marker of anaerobic glycolysis and revealed a 
4 fold increase (p=0.001) whilst TCA intermediaries/glucose demonstrated a 50% reduction 
in malignant tissue (p=0.001).  There was an insignificant increase in lactate/TCA 
intermediary ratio seen in malignant tissue (1.10 fold increase, p=0.349). 
 
 
Metabolite ratio 
Fold change 
in malignant 
tissue 
p 
Lactate:Glucose 4.32 0.0001 
TCA cycle:Glucose 0.44 0.001 
Lactate:TCA cycle 1.09 0.349 
Table 4.3 - A significant increase in Lactate:Glucose ratio is observed in malignant 
tissue. 
All values are presented as relative to the mean concentration in normal tissue.  Significance 
was assessed using 2-tailed t-test with unequal variances assumed. 
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4.3.5 Increased amino acid is seen in tumour samples 
11 amino acids were identified in the sample spectra.  Of these, isoleucine, leucine, valine, 
glutamate and taurine showed a significant increase in malignant tissue (Figure 4.7).  Of the 
remainder, most showed a trend towards increase in malignant tissue.   Both dietary essential 
as well as non-essential amino-acids were increased implying that the increase arises, at least 
in part, from catabolic processes, rather than increased biosynthesis.  Fumarate and isocitrate 
were the only TCA cycle intermediaries identified.  Fumarate demonstrated a significant 
decrease in malignant tissue but no change was observed in isocitrate.   
The correlation between metabolites was assessed by construction of heatmaps (Figure 3.4).  
Significant correlation (both positive and negative) was observed in normal tissue between 
metabolites with the strongest correlation between ketogenic amino-acids.  There was a 
strong negative correlation observed between isocitrate and most of the amino-acids.  In 
normal tissue, amino-acids continued to cluster together but the relationship between 
isocitrate and amino-acids was somewhat lost. 
Glutamine and glutamate represented the only two adjacent metabolite pair identified and 
demonstrated a strong positive correlation in normal tissue consistent with the conversion of 
glutamine into glutamate.   The ratio of glutamine/glutamate was significantly reduced in 
malignant tissue and could be due either to an increase in glutaminase expression or a 
reduction.  
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Figure 4.7 - Amino acid levels are altered in malignant tissue 
All concentrations are presented relative to the mean of normal tissue.  Normal tissue is 
shown in black and malignant tissue in red.  A statistically significant increase (p<0.05) was 
seen in isoleucine, leucine, valine, glutamate and taurine.  With the exception of glutamine all 
others showed a trend towards increase.  Glutamine decreased but failed to reach statistical 
significance.  
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Figure 4.8 - Correlation between amino-acids and TCA cycle intermediaries in normal 
and malignant tissue 
Significant correlation (both positive and negative) was observed in normal tissue between 
metabolites with the strongest correlation between ketogenic amino-acids.  There was a 
strong negative correlation observed between isocitrate and most of the amino-acids.  In 
tumour tissue, amino-acids continued to cluster together but the relationship between 
isocitrate and amino-acids was somewhat lost. 
Normal Tissue 
Tumour 
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4.3.6 Choline containing compounds are significantly increased in colorectal cancer 
The spectral region 3.19-3.23 contained 3 resonances corresponding to Choline, 
phosphocholine and glycerophosphocholine.  Analysis of the loadings plot of the PCA  model 
discriminating between normal and malignant tissue (Figure 4.4) demonstrated that these 
resonances contributed towards the differences seen between the two tissue types.  Initial 
attempts at quantifying these metabolites using matlab software as previously described 
demonstrated that all were increased in malignant tissue but not to statistical significance.  
This was thought to be due to the significant overlap between the 3 resonances makes 
accurate integration of the areas under the peaks impossible.  Chenomx software permits the 
fitting of multiple overlapping peaks using an inbuilt library of previously profiled 
compounds and the choline resonances were therefore manually integrated using the 
Chenomx software.  This was performed on unprocessed,  non-normalised spectra, results 
were normalised to the initial tissue mass used to prepare the extract. 
Figure 4.9 shows the region of the spectra corresponding to the choline containing 
compounds as well as the changes in relative concentrations.  Using this technique, in 
malignant tissue, a significant increase was seen in all the total choline containing compounds 
as well as the 3 compounds individually.  In addition, the ratio of glycerophosphocholine to 
phosphocholine was significantly reduced in malignant tissue, a phenomenon previously 
described as the glycerophosphocholine switch.
142
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Figure 4.9 – Choline containing compounds are increased in malignant colorectal tissue 
The concentrations of choline, PC and GPC are presented relative to the mean of normal 
tissue.  The ratio GPC/PC is one of absolute concentration.  A statistically significant increase 
(p<0.05) was seen in choline, PC and GPC concentrations.  A significant decrease was seen 
in the GPC/PC ratio.  
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4.3.7 Uracil and its nucleotide sugars are increased in malignant tissue 
Uracil was confidently assigned to two distinct doublets visible in the spectra that had strong 
correlation on STOCSY analysis.  A further two spectral regions were good candidates for 
uridine and assigned on this basis although at both chemical shifts and in all specimens some 
artefact was observed leading the spectra to deviate below the baseline.   UDP-glucose was 
assigned on the basis of STOCSY analysis to the peak at 5.99 although the close proximity of 
other UDP-sugars mean that the assignment of UDP-glucose cannot be certain and the peak 
probably represents a combination of UDP-glucose, UDP-galactose and UDP-glucuronate. 
Uracil and UDP-glucose were significantly increased in malignant tissue whilst uridine was 
significantly reduced (Figure 4.10).  A strong correlation was observed between uridine and 
uracil and between UDP-glucose and uracil in normal tissue although the latter correlation 
lost significance in malignant tissue.  No correlation was observed between uridine and UDP-
glucose in either normal or malignant tissue no further uridine products were identified for 
quantification.   
As before, ratios of adjacent metabolites were compared between normal and cancerous 
tissue to estimate the pathway activity.   Products were compared to the sum of the available 
reactants (Table 4.4).   
Inosine, hypoxanthine pyridoxine and niacinamide were all identified in the spectra but 
demonstrated no significant change in malignant tissue.  
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Figure 4.10 - Change in uracil and related compound concentrations in malignant tissue 
All values are presented as relative to the mean of normal tissue.  Normal tissue is shown in 
white and malignant tissue in red.  A significant increase (p<0.05) was seen in Uracil and 
UDP-glucose.  A significant fall was seen in uridine.  The strong correlation between uridine 
and uracil seen in normal tissue was somewhat lost in malignant tissue.  
 
 
Metabolite ratio 
Fold change in malignant tissue p 
UDP-Glucose:Uridine 1.76 0.030 
UDP-Glucose:(Uridine+Uracil) 1.2 0.011 
Uridine:Uricil 0.557 0.071 
Table 4.4 - A significant increase in UDP-Glucose:Uridine ratio is observed in 
malignant tissue. 
All values are presented as relative to the mean concentration in normal tissue.  Significance 
was assessed using 2-tailed t-test with unequal variances assumed.  
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4.3.8 Changes were observed in the nucleotide levels and ratios in malignant tissue 
A number of peaks were identified in the aromatic region of the spectra that corresponded to 
nucleotides and their derivatives.  A significant amount of arbitrary baseline interference in 
relation to the signal intensity (signal to noise ratio) made definitive assignment difficult.  
This was compounded by the close proximity of chemical shifts in the region.  In order to 
attempt assignment, a STOCSY analysis was performed of the peaks in the region appeared 
to reveal 2 distinct molecules the most likely candidates for which were AMP and ATP 
(Figure 4.11).     
A 2 fold increase in AMP was observed in tumour samples compared to normal (p<0.001) 
(Figure 4.12) whilst the integrals corresponding to ATP decreased in tumour samples.  Whilst 
the latter was not statistically significant, the relative change in both is suggestive that the 
average adenlyate energy charge is reduced in the tumour samples, although cannot be 
accurately calculated in the absence of knowledge of the ADP concentration.   Adenylate 
energy charge has been observed to transiently decrease in respond to tissue hypoxia,
143
 and 
the hypoxic microenvironment of colorectal cancer would provide an explanation for the 
effect observed here.   
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Figure 4.11 - STOCSY demonstrating the integrals correlating to AMP and ATP. 
STOCSY was performed on the singlets at δ6.12 and δ6.16.  When the doublet at δ6.12 was 
used as a driving peak (a), significant correlation was seen in singlets at δ8.22 and δ8.35 
suggesting AMP as a possible assignment.  When δ6.16 was used as a driving peak (b),  
correlating singlets were identified at δ8.28 and δ8.61 which may represent ATP.  
 
(a) 
(b) 
(a) 
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Figure 4.12 - Mean integrals corresponding to the nucleotides identified in tissue 
samples. 
Relative concentrations of AMP and Uracil were significantly increased in AMP and Uracil 
(p<0.001). ATP concentration decreased but the result was not significant.  Normal tissue is 
shown in white and cancerous tissue shown in red. 
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4.3.9 Myoinositol Levels are significantly reduced in malignant tissue 
A number of peaks corresponded to myoinositol, a stereoisomer of the the cyclohexane 
alcohol, inositol.  It forms the basis of the inositol phosphates, which act as secondary 
messengers in human cells as well as forming the structural lipid phosphatidylinositol.  No 
other such compounds were identified in the spectra.  Myoinositol levels was consistently and 
significant reduced in malignant tissue to 73% of that seen in normal tissue (Figure 4.13).   
 
 
Figure 4.13 – Myoinositol levels are reduced in malignant tissue 
Myoinositol levels were significantly reduced in malignant tissue to 0.73 of that seen in 
normal tissue (p<0.01).   
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4.3.10 Summary of Findings 
A summary figure of the changes in the metabolites identified is shown in Figure 4.14.  
Those metabolites with significant integral changes are shown in red.   
 
Figure 4.14 - Comparison of metabolites between cancer and normal tissue. 
Red columns  indicate those that reached statistical significance (p<0.05) using students t-test 
with Welch’s correction.  
(3) (2) (1) 1 2 3
Glucose
Pyridoxine
Creatine phosphate
Myoinositol
PEG
Fumarate
Scylo-inositol
Uridine
Glutamine
3-Hydroxybutyrate
 Creatine
 Inosine
Lysine
Glycerophosphocholine
Hypoxanthine
Choline
 Tyrosine
Glycine
 Niacinamide
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5 Can Metabonomics Contribute to Colorectal Cancer Staging? 
5.1 Introduction 
In section 1, some of the current challenges in the diagnosis and management of CRC are 
highlighted.  It is clear, that many of these challenges relate to the inability of the clinician to 
individually tailor treatment to a particular patient.  The development of biomarkers to 
stratify patients would offer this opportunity.  In order to justify the seemingly relentless 
pursuit of colorectal (and other cancer) biomarkers, it is first worth considering the 
hypothetical characteristics of the ‘perfect biomarker’ (Table 5.1).   To date, clearly nothing 
has come close to exhibiting all of these characteristics, but some appear to be close to some 
of the characteristics.  Attention has been focussed on identifying potential markers for all 
stages of the disease and even identifying those at risk of developing cancer ie in the pre-
cancerous stage.   
Risk 
Identify those individuals at 
risk at a pre-disease stage 
 Minimally invasive 
Screening 
Earliest diagnosis confers 
greatest survival 
100% Sensitivity 
 
Prognostic  
Identify those patients most 
likely to benefit from adjuvant 
therapy 
 
Inexpensive 
Predictive 
Provide individualised 
treatment 
100% Specificity 
 
Recurrent 
Identify early relapse and treat 
early 
 
Acceptable 
Table 5.1  - Properties of an ideal biomarker 
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Carcinoembryonic antigen (CEA) is the most widely established colorectal cancer biomarker 
in current use but its poor sensitivity for early stage cancers limits is use for the detection of 
cancer recurrence during followup.  In one study it demonstrated a sensitivity of only 18% for 
the detection of early malignancy increasing to 84% in later stage disease
144
.  Consequently it 
is of limited value for the diagnosis of new disease and attention has turned to alternative 
molecular markers.   
In the previous chapter, the metabolic phenotype of normal and malignant tissue was 
characterised by the identification, measurement and comparison of known metabolites.  
Whilst it was able to determine significant differences between normal and malignant tissue it 
is a labour intensive technique that requires visual inspection and identification of individual 
metabolites within the spectra.  Consequently, a relatively low number of metabolites are 
considered – ie those easily visually identified from the spectra.   
The spectra may contain a significant amount of latent information not easily characterised 
from visual inspection either due to poor resolution or low concentrations.  Furthermore,  the 
characterisation of colorectal tissue in the previous chapter included only those metabolites 
which could be readily assigned to known metabolites;  a number of peaks in the spectra were 
not assigned leaving a potentially large amount of data unconsidered.    To consider this 
potentially latent information requires the spectra to be compared in totality rather than 
individual comparisons of peaks.  The vast number of variables and relatively small number 
of samples or observations require multivariate statistical techniques as described in the 
materials and methods chapter.   
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5.2 Experimental Design 
Samples were processed and analysed by 1H NMR as previously described.  The lipid and 
aqueous extracts of the entire sample set was analysed and these data were used as the 
training set to construct discriminatory statistical models and identify potential biomarkers.  
A separate tissue sample was taken from a subset patients and was analysed whole by the 1H 
NMR magic angle spin method and this latter set used as a test  set to produce Receiver 
Operating Characteristic curves of any potential biomarkers.    Clinicopathological data was 
collated as previously described.    
Raw data was pre-processed as described in the previous chapter and bucketed into bins of 
0.01ppm size samples for further analysis.  This data was imported into SIMCA for statistical 
analysis along with the clinicopathological data.  Several different scaling strategies were 
used where appropriate and are described below.   Models were constructed for the various 
clinical and pathological characteristics and were examined.  Where significant models were 
obtained and potential biomarkers identified they were cross-validated internally and with the 
second sample set analysed by magic angle spinning.   
5.3 Results 
5.3.1 Biomarkers discriminating between normal and cancerous tissue 
To examine the overall distribution of the data and identify any potential outliers, a non-
supervised PCA model was initially constructed (Figure 5.1).  Even without a-priori 
knowledge of the sample class the samples clustered broadly into cancer and normal tissue 
although the model was weak (R
2
X = 0.363, Q
2
=0.249).  Inspection of the scores and DMOD 
plot revealed one sample to be a strong outlier (patient 2, cancerous tissue).  The original 
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CPMG and NOSEY spectra acquired for this sample were inspected but no obvious artefact 
was identified and it was therefore included in further analysis. 
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A
 
B
 
Figure 5.1 – Unsupervised PCA model of the entire aqueous extract dataset. 
The scores plot of the model is shown in (A) and the DMOD plot from the same model 
shown in (B).  Model characteristics R
2
X = 0.363, Q
2
=0.249.  The data was UV scaled.  
Normal tissue is shown in black and cancerous tissue in red.  Only the outlier (patient 2) is 
labelled. 
A supervised PLSDA model was constructed to identify potential biomarkers discriminating 
between normal and cancerous tissue (Figure 5.2).  A robust model was generated showing 
good separation between the classes (R2Y=0.696, Q2=0.491) within the first two components 
and the scores plot revealed that the vast majority of class separation occurred within the first 
component. The reliability of the model was assessed by analysis of variance testing of the 
cross-validated predictive residuals (CV-ANOVA) and revealed a highly significant result 
(p<0.001).  A validation plot was constructed using 100 permutations to determine the degree 
of overfit of the model.  Examination of the loadings plots revealed a number of different 
metabolites contributing strongly to the model.  SIMCA-P+ allows these to be quantified by 
calculation the variables contribution to the overall model and is measured in arbitrary units.   
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Figure 5.2 - PLSDA model of the aqueous extract dataset. 
The scores plot is shown with normal tissue shown in black and cancerous tissue in red. The 
model was cross validated with 100 permutations.  Cumulative R2 (green) and Q2 (blue) are 
shown.  The loadings plots from the 1
st
 and 2
nd
 components and a loadings line graph of the 
first component.  
121 
 
 
Table 5.2 lists the 40 most significant variables which correspond to 8 metabolites.  No 
unclassified peaks were appeared to contribute significantly to the model. 
 
Chemical Shift (ppm) VIP Value Metabolite 
3.26085 6.29674 Taurine (myoinositol) 
3.40935 5.75768 Taurine 
3.2691 5.43252 Taurine 
3.4176 5.38965 Taurine 
3.2526 5.21596 Taurine 
3.4011 5.14692 Taurine 
1.33035 5.09071 Lactate 
3.42585 4.90728 Taurine 
3.54135 4.85473 Myoinositol 
3.6156 4.71772 Myoinositol 
3.5331 4.55812 Myoinsitol 
1.31385 4.29411 actate 
3.52485 4.25271 Myoinositol 
4.0611 4.18596 Myoinositol 
3.6981 4.13801 PEG 
1.3221 3.79286 Lactate 
3.5166 3.71684 Myoinositol 
3.6321 3.70261 Myoinositol 
3.5991 3.60933 Myoinositol 
3.02985 3.36159 Creatine(phosphate) 
3.70635 3.29789 PEG 
3.62385 3.19787 Myoinositol 
3.0381 3.1592 Creatine(phosphate) 
2.3451 3.06807 Glutamate 
3.27735 2.97148 Taurine(myoinositol) 
2.33685 2.92393 Glutamate 
3.92085 2.84363 Creatine 
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3.60735 2.80959 Myoinositol 
3.34335 2.76233 Unidentified 
4.06935 2.70508 Myoinositol 
2.05635 2.68973 Glutamate 
3.21135 2.66957 Glycerophosphocholine 
2.3286 2.65212 Glutamate 
2.07285 2.58105 Glutamate 
7.67295 2.57153 Pyridoxine 
3.64035 2.56546 Myoinositol 
2.0646 2.45107 Glutamate 
4.05285 2.44165 Myoinositol 
2.35335 2.40883 Glutamate 
3.29385 2.21726 Taurine & Myoinositol 
 
Table 5.2 – List of variables contributing to normal/cancer class separation ordered by 
variable importance. 
All of the peaks identified were assigned to metabolites.  The Variable Importance Plot (VIP) 
value is an arbitrary reflection of how significantly the peak contributes to the class 
separation shown in Figure 5.2.   
 
With the exception of pyridoxine (δ7.67), all of the metabolites contributing to the model 
were from the aliphatic region of the spectra.  The remainder of the aromatic region appeared 
to contribute little to the model.  In order to determine whether this region was under-
represented as a result of the low intensity of peaks seen in this region a new model was 
constructed with all variables scaled to unit variance.  Whilst a reasonable model was 
generated (R2X=0.206,Q2=0.491, CV-ANOVA p<0.001), the loadings plot revealed little 
meaningful information as a result of poor signal to noise ratios and is not shown.  
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To attempt to overcome the signal to noise problem a PLSDA model was created using 
integrals of all visually identified peaks, including unclassified peaks (Figure 5.3).  As noise 
had been manually excluded, full UV scaling was applied.  The resultant model was assessed 
for significance in the same way as previously by CV-ANOVA and was significant 
(R2X=0.354, Q2=0.44,p<0.001).  Cross validation showed little over-fit of the model. 
The loadings plot revealed similar characteristics to the previous model, being dominated by 
taurine, glutamate and myoinositol, although this time lactate appeared to be less significant.  
Several unclassified peaks appeared to contribute to the class separation.  Of the peaks from 
the aromatic region of the spectra, only pyridoxine, uracil, AXP and an unidentified peak at 
6.13 contributed.   
Of note, different integral areas assigned to the same metabolite did not always always cluster 
together.  The areas corresponding to myoinositol, for example,  largely cluster together with 
the exception of one area that appears on the opposite side of the loadings plot implying that 
this peak may have been misclassified. 
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Figure 5.3 - PLSDA model of aqueous extracts constructed using integral intensities. 
Normal Tissue is shown in black and tumour tissue in red.   
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5.3.2 Organic extracts of colorectal tissue discriminate weakly between normal and 
cancerous tissue. 
Organic extracts of the tissue samples were prepared and analysed as previously described.  
Visual inspection revealed a number of 4 obviously abnormal spectra and these were 
excluded from further analysis.  Spectra were normalised and bucketed to 0.001 ppm as 
previously described (Section 3.8) and imported into SMCA-P for further analysis.  As no 
library exists of organic data extracts, characterisation of the peaks from the organic spectra 
was not attempted until such times as a candidate biomarker was identified. 
Unsupervised PCA of the data is shown in Figure 5.4.  The data showed a good fit to the 
model (R2=0.802, Q2=0.668) with 2 notable outliers.  Again, the spectra from these outliers 
were inspected to check for any obvious abnormality but as none were found they were 
included in subsequent analysis.  No clear separation was seen between groups of 
observations.  Although there was obvious clustering of approximately half of the 
observations this was not by normal vs cancerous tissue.  Various different classifications 
were considered but none of the clinical or pathological information available for the patient 
samples was responsible for the separation seen.  The loadings plot for this model showed a 
number of clear peaks including some already considered in the aqueous extracts (e.g. 
lactate).   
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Figure 5.4 - Unsupervised PCA model of the organic tissue extracts. 
Normal tissue is shown in black and tumour tissue shown in red.  (R2=0.802, Q2=0.668). 
 
To  attempt to discriminate between normal and cancerous tissue, a PLSDA model was 
constructed (Figure XX).  The model characteristics were weak but just significant 
(R2Y=0.337, Q2=0.164, p<0.05), but a degree of over-fit was observed.   The normal tissue 
appeared to cluster more closely than the cancerous tissue.  Inspection of the loadings and 
variable importance plot several peaks contributing towards the model.  Other than lactate 
which was clearly visible these were uncharacterised and not apparent in the aqueous spectra.  
Spectral areas with a VIP coefficient of >2.5 were included, uncharacterised, as candidate 
biomarkers. 
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Figure 5.5 – PLSDA model constructed from organic tissue extracts. 
The scores plot is shown with normal tissue in black and tumour tissue shown in red. 
(R2Y=0.337, Q2=0.164, p<0.05).  Data was mean centred and parieto scaled.  R2Y=0.337, 
Q2=0.164, p<0.05.  The model was cross-validated with 100 permutations: R2 is shown in 
green and Q2 in blue.  The variable importance plot is shown.   
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5.3.3 Discriminating tissue by pathological stage 
PLSDA models were created for the samples by histological data (Figure 5.6).  Normal and 
cancerous tissue were modelled separately.  Models were constructed using spectral data 
from the aqueous tissue extracts as well as the organic extracts bucketed to 0.01ppm.  
PLSDA was unable to discriminate aqueous or organic tissue extracts by Dukes’ stage for 
either normal or cancerous tissue.  When Dukes’ B cancers were excluded and the model 
reconstructed using Duke’s A and C as classifiers, it was possible to generate a model 
separating the tissue classes from the aqueous tissue extracts in the normal tissue but this 
failed to reach significance when assessed by CV-ANOVA testing (p=1), the validation plot 
showed substantial over-fitting and the scores plot revealed no meaningful information;  this 
model was therefore discounted.  Grouping of stages together i.e. Dukes’ A&B vs Dukes’ C 
also failed to generate a model capable of discriminating between the classes.    None of the 
spectral data from the organic fraction of the tissue extracts was able to generate a 
discriminatory model for any combinations of Dukes’ classification for normal or malignant 
tissue.   
The histological presence of extramural vascular invasion was used to classify tissue samples 
but failed to generate discriminatory PLSDA models in either the aqueous or organic tissue 
extracts for the normal or cancerous tissue.  
Classification of the normal tissue samples by nodal status +ve or –ve also failed to generate 
a discriminatory model for either the aqueous or organic tissue extracts or for the cancerous 
organic tissue extracts. 
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Figure 5.6 - Overview plots for PLSDA models created using discriminating 
histopathological data. 
R
2
Y is shown in green and Q
2
 shown in blue.  All data was parieto scaled.  None of the 
models reached statistical significance measured by cross-validation ANOVA testing.  
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It was possible to construct a weak model with the cancerous aqueous tissue extracts that 
discriminated between node +ve and node –ve tissue samples (R2X=0.381, Q2=0.329) 
(Figure 5.7).  Although inspection of the validation plot showed that the model appeared to 
be over-fitted, it did reach statistical significance (p<0.05) and the loading plot was therefore 
examined for possible candidate biomarkers.  A considerable amount of baseline interference 
made the scores plot difficult to interpret.  Associated with this, the regions that appeared to 
be of particular interest were around the choline, creatine, branched chain amino acid and 
taurine metabolites.  The bucketed data did not permit accurate resolution of the individual 
metabolites within these regions therefore the models were repeated using the spectral data 
bucketed to 0.001ppm.   This yielded a model with similar characteristics to the previous one 
(R2X=0.213, Q2=0.256) and showed a similar degree of overfit, but was not statistically 
significant when assessed by CV-ANOVA (p=0.1).  The branched chain amino acids 
isoleucine and leucine appeared to contribute strongly towards the model in favour of node 
+ve along with creatine.  Creatine phosphate did not appear to contribute.  Choline and 
phosphocholine made significant contributions in favour of node –ve samples but not 
glycerophosphocholine.  Also in favour of node –ve samples were alanine, taurine and an 
unidentified metabolite – the singlet apparent at 3.32ppm.  All of these metabolites were 
selected as candidate biomarkers to assess nodal status.   
Finally, all models were reattempted utilising the integrated areas under discreet peaks as 
previously described but this also failed to generate any meaningful discriminatory models.   
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Figure 5.7 - PLSDA model discriminating node +ve from node -ve cancerous tissue 
samples.  
A weak model was generated with low predictive ability separating node +ve and node-ve 
malignant tissue but reached  statistical significance when assessed with CV-ANOVA testing 
(R
2
X=0.381, Q
2
=0.329, p<0.05) 
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Figure 5.8 – PLSDA loadings plot of bucketed aqueous tissue extract data 
discriminating node +ve from node –ve cancerous tissue 
The data was bucketed to 0.001ppm in and revealed isoleucine and leucine contributing in 
favour of node positive status along with creatine.  Choline  and phosphocholine contributed 
towards node negative staus.   (R2X=0.213, Q2=0.256, CV-ANOVA p=0.1) 
 
5.3.4 PLSDA Modelling is unable to discriminate tissue by site 
 Specimens were categorised according to the site of the tumour into rectal, recto-sigmoid 
and intra-peritoneal colon.  PLSDA models were then constructed using data from the binned 
aqueous and organic tissue extract spectra as well as the integrated spectral regions from the 
aqueous spectra.  None of these data were able to produce robust models discriminating 
between the three anatomical locations for normal or tumour tissue.  Tumours arising in the 
recto-sigmoid and distal sigmoid were excluded in order to establish whether PLSDA could 
discriminate between the most proximal and distal specimens but this too failed to generate 
any valid models (Figure 5.9).   
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Normal tissue – Anatomical location
 
Cancerous tissue – Anatomical location
 
Normal tissue – rectal vs intraperitoneal
 
Cancerous tissue – rectal vs 
intraperitoneal
 
Figure 5.9 – Overview plots for PLSDA models constructed to discriminate tissue by 
anatomical location. 
R
2
Y is shown in green and Q
2
 shown in blue.  All data was parieto scaled.  None of the 
models reached statistical significance measured by cross-validation ANOVA testing.  
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5.3.5 Discriminating tissue by sex 
In order to establish whether there were any baseline differences between male and female 
colorectal tissue and whether the tissue moved towards a common malignant phenotype, 
samples were classified according to the sex of the patient and models constructed for normal 
and malignant tissue.   PLSDA failed to discriminate between these groups using data from 
the aqueous and organic tissue extracts for normal tissue and between sex for the cancerous 
organic tissue (Figure 5.10).  Classification by sex in the cancerous aqueous tissue samples 
however produced a discriminatory model. 
Male and female cancerous aqueous tissue extracts showed clear separation in a PLSDA 
model (R
2
X=0.236, Q
2
=0.891).  Although the model showed some degree of over-fit, it was 
statistically significant when assessed by CV-ANOVA (p<0.05).  Inspection of the loadings 
plot revealed that lactate (raised in females) and the  branched chain amino acids isoeleucine, 
leucine and valine (raised in males) were contributed most to the class separation.    
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Normal tissue by sex (aqueous extracts)
 
Cancerous tissue by sex (aqueous extracts) 
 
Normal tissue by sex (organic extracts) 
 
Cancerous tissue by sex (organic extracts) 
 
Figure 5.10 - Overview plots for PLSDA models discriminating tissue by sex 
R
2
Y is shown in green and Q
2
 shown in blue.  All data was parieto scaled.  None of the 
models reached statistical significance measured by cross-validation ANOVA testing.  
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Figure 5.11 – PLSDA model discriminating aqueous cancer samples by sex 
Males are shown as blue crosses and females as red circles.  (R
2
X=0.236, Q
2
=0.891), CV-
ANOVA (p<0.05). 
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5.3.6 Validation of candidate biomarkers 
Whilst the previous PLSDA models had been validated by cross-fold validation, in a further 
attempt to validate the models generated, a random subset of 30 samples was selected from 
those available for separate analysis by 
1
H MAS Spectroscopy – ‘the external validation set’.  
14 normal samples and 16 cancer samples were analysed.   
After MAS, the water region was removed and spectra were normalised to the median fold 
change within the subset as with the tissue extracts.  Whilst all spectra were of good quality 
not all candidate biomarkers were obvious by visual inspection of the spectra.  In particular, 
peaks identified in the organic tissue extracts were not readily visible in the whole MAS 
spectra and the resolution of the region containing several nucleotides and their derivative 
was poorly resolved (5.6-8.2ppm, 8.2-10.0ppm).  Median MAS spectra are shown at Figure 
5.12. 
 
Figure 5.12 – Median CPMG spectra obtained from MAS of validation set 
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The spectra obtained from the external validation set were aligned to those obtained from the 
tissue extracts, had the same water region removed and bucketed into 0.01ppm regions after 
being normalised to their own median fold change as previously described.  Following this 
they were uploaded  into SIMCA as a validation set.  The previous models were used to 
obtain YPred values for this validation set from which receiver operating characteristic 
(ROC) curves were obtained.  These were compared with the ROC generated from the Ypred 
values of the training set using 7 fold cross validation.   
The model used to discriminate between normal and cancerous tissue generated a ROC with 
area under the curve (AUC) of 0.996 utilising the training set.  The YPred values from the 
validation set yielded an AUC=0.741 (Figure 5.13). 
 
 
Figure 5.13 – ROC curves for tumour vs normal tissue 
The same approach was attempted using the YPred values obtained from the models 
constructed to predict node states (+ve or –ve) and sex.  The predictive value of the models 
using the validation set was poor with AUC=0.533 for node status and AUC=0.521 for sex 
(Figure 5.14).   
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As the validation spectra were obtained using a different platform from the training data, and 
differences in spectral baseline and pH shifts of the spectra may be due to these differences, a 
further attempt was made to validate the data utilising the integral intensities from all 
identifiable metabolites.  Using this data, PLSDA models could be created from the training 
set predictive of tumour/normal, node status in cancer tissue and sex in cancer tissue as 
before however were generally weaker.  No increase in predictive value of the model was 
seen when the validation data was used (data not shown). 
 
Figure 5.14 – ROC Curves for node status and sex 
 
Finally, based on their contribution to the previously constructed models, a panel of candidate 
biomarkers were considered where they had shown the potential to reliably distinguish 
between malignant and normal tissue (Table 5.3) and between sex and nodal status in 
malignant tissue (Table 5.4).   To attempt to ensure reliable measurement of each metabolite 
with spectroscopy, where a metabolite had several peaks, the most discreet peak on the 
spectra was chosen for measurement in an attempt to avoid nearby and overlapping 
resonances interfering (Table 5.3).  
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 Classification Sample Metabolite Chemical shift (ppm) 
Tumour/Normal Aqeuous Taurine 3.26 (t), 3.41 (t) 
  Myoinositol 3.27 (t), 3.53 (dd), 3.62 (t), 4.06 (t) 
  Lactate 1.32 (d), 4.11 
  PEG 3.70 
  Creatine phosphate 3.04 
  Glutamate 2.05, 2.13, 2.34, 3.76 
  Pyridoxine 7.67 
  Uracil 5.79, 7.54 
  AXP 6.14, 8.27, 8.60 
  Uncharacterised A 6.13 
 Organic Uncharacterised B 0.88 
  Uncharacterised C 1.67 
  Uncharacterised D 3.64 
  Uncharacterised E 7.25 
Table 5.3 – Candidate biomarkers discriminating between normal and cancerous tissue  
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Classification Sample Metabolite Chemical shift (ppm) 
Nodal Status Aqueous Isoleucine 0.93 (t) 
  Leucine 0.96 (d) 
  Taurine 3.26 (t), 3.41 (t) 
  Creatine 3.03 
  Choline 3.19 
  Phosphocholine 3.21 
Sex Aqueous Lactate 1.32 (d) 
  Isoleucine 0.93 (t) 
  Leucine 0.96 (d) 
  Valine 0.98 (d) 
Table 5.4 – Candidate biomarkers discriminating between nodal status and sex in 
malignant tissue 
 
 
Relative measurement of each metabolite was made by integrating the area under the 
candidate biomarker peak in MATLAB as previously described.  Receiver operating 
characteristic (ROC) curves were then constructed for each candidate biomarker using the 
spectral data used to construct the PLSDA models (training set).  
As individual metabolites, none of the candidate biomarkers demonstrated strong predictive 
ability for any of the models with the exception of a single taurine resonance which yielded 
an AUC=0.848 when predicting tumour or normal tissue in the validation set (Figure 5.13 
and Figure 5.14).   
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Figure 5.15 - ROC Curve for selected candidate biomarkers discriminating cancer from 
normal tissue 
ROC curves were calculated using integrals of selected biomarkers from the variable 
importance plots contributing to the discriminatory models.  With the exception of a single 
Taurine resonance (AUC=0.848) none of the candidate biomarkers demonstrated strong 
predictive ability.  
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Table 5.5 - ROC Curve for selected candidate biomarkers discriminating nodal status 
and sex in malignant tissue.  
ROC curves were calculated using integrals of selected biomarkers from the variable 
importance plots contributing to the discriminatory models.  None of the candidate 
biomarkers demonstrated strong predictive ability.  
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5.4 Summary 
1
H MAS NMR spectroscopy was utilised in order to externally validate a series of PLSDA 
models and putative metabolic markers of disease indices in colorectal cancer with mixed 
success.  Predictive models could be generated capable of discriminating between cancerous 
and normal tissue which appeared to be robust but when validated against an external data set 
showed lower predictive ability.  Attempts to generate models predictive of pathological 
stage and other pathological and clinical state were largely unsuccessful. 
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6 Metabolome changes in chemoresistance to 5-FU 
6.1 Introduction 
5-FU forms the basis of many first line chemotherapy regimens for the treatment of colorectal 
cancer.  It is a cell cycle phase specific anti-metabolite drug which, during S phase, exerts its 
anticancer effects via two main mechanisms: through miss-incorporation into RNA during 
synthesis, disrupting normal RNA processing and function, and by inhibition of thymidylate 
synthase, the enzyme responsible for providing the de novo thymidylate required for DNA 
replication and repair
145
. 
Although the response rates for single agent chemotherapy utilising 5-FU are low 
(approximately 10-15%) this rises when combined with other agents such as oxiplatin.  
Despite this, approximately 50% of tumours fail to respond to chemotherapy which is thought 
to occur via a variety of mechanisms.  Amongst these is the ability of some cancer cells to 
evade chemotherapy induced cell death by modulation of the apoptopic pathway.  
Chemotherapy and Apoptosis 
The disruption of the cell cycle by 5-FU initiates the apoptopic cascade which can also be 
induced directly by the drug.  Ordinarily, apoptosis is highly regulated and can be activated 
by either an intrinsic or extrinsic pathway.  Most chemotherapy agents appear to induce 
apoptosis via the intrinsic pathway and the activation of caspases.   
FGF-2 is a small polypeptide belonging to the FGF family of 22 members, which were 
originally identified as proteins capable of stimulating fibroblast proliferation.  Recently, 
fibroblast growth factor (FGF)-2 they have been suggested to play a role in tumour 
development and in conferring tumour resistance to chemotherapeutic agents 
146
.  FGF-2 is 
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known to be overexpressed in several human malignancies and is expressed in the majority of 
colorectal tumours.  In addition to its role in signalling tumour cell growth there is evidence 
that it contributes to chemoresistance which in breast cancer cell lines appears to occur by 
inhibiting apoptosis albeit with another agent 
147
. 
Work previously performed in this department has demonstrated that in colorectal cancer 
cells lines there is a variable response to FGF-2 induced chemoresistance.  In SW620 cells (a 
metastatic human colorectal cancer cell line), FGF-2 conferred a protective benefit to cells 
treated with 5-FU chemotherapy that occurred by attenuation of cellular apoptosis.  This 
benefit was not seen in SW480, a primary colorectal cancer cell line. This was not as a result 
of increased FGF receptor expression nor via induction of the anti-apoptotic proteins Bcl-2 or 
Bcl-XL. Figure 6.1 is reprinted with permission from ‘Fibroblast growth factor-2, 
chemoresistance and colorectal cancer’, MD(res), 2012 ‘148.   
This study aims to investigate the known variation in response between a primary human 
adenocarcinoma cell line (SW480) and a metastatic cell line taken from the same patient 
(SW620) by 1H NMR spectroscopy.  The metabolic perturbations associated with apoptosis 
and FGF-2 induced chemoresistance in SW620 and SW480 colorectal cancer cells will be 
investigated and whether their differences in chemosensitivity can be related to the metabolite 
changes observed in earlier chapters. 
6.2 Experimental Design 
2 different cell lines, SW480 and SW620 were treated with 5FU, 5FU&FGF2 and FGF2 
alone.  A control group was analysed for each cell line.  Cells were followed across 4 time 
points from 24 to 96 hours and analysed at each.  Experiments were repeated in duplicate.   
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Figure 6.1 – Selective inhibition of 5-FU induced apoptosis by FGF-2. 
(from Prabhuesai et al. Fibroblast growth factor-2, choresistance and colorectal cancer
148
) 
FGF-2 conferred a protective benefit to SW480 cells but not SW620 cells (a) which occurred 
through a reduction in apoptopic activity as measured by Caspase 3/7 assay.   
  
SW480 SW620 
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6.3 Results 
6.3.1 NMR spectroscopy of treated cell media 
An unsupervised principle component analysis was performed on all samples to establish any 
obvious outliers in the data and determine any clear trends from the outset.  This analysis 
showed a clear separation between SW480 and SW620 cells in the 1
st
 component and a clear 
time related shift observed in both cell types through time in the 2
nd
 component (Figure 6.2). 
 Changes in metabolites in response to cells were unsurprising and confined to relatively few 
metabolites.  Of these the most significant were lactate (δ1.32) which increased over time and 
variables that appeared to represent choline containing compounds (δ3.22 and δ3.23) which 
decreased as time progressed.  Identifying which metabolites were responsible for differences 
in the cells was less clear but again, a choline containing compounds appeared to separate in 
this component. 
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Figure 6.2 - The metabolic profile of SW480 and SW680 cells 
Unsupervised PCA scores and loadings plots of all treatment groups, time points and cell 
types.  The scores plot is labelled by time point and SW480 cells are shown in red and 
SW620 cells shown in green.  The loadings plot is also shown with the bucketed spectral 
intensity shown.   
 
6.3.2 FGF-2 has no effect on the metabolic profile of SW480 or SW620 cells 
It is known that FGF has a proliferative effect on both cell lines but no clear difference 
between those cells pre-treated with FGF had been identified from untreated cells in the 
unsupervised PCA model above.  To confirm this, attempts were made to construct a model 
comparing the untreated cells and those pre-treated with FGF.  SW480 and SW620 cells were 
considered together but no PLSDA model could be constructed discriminating the treatment 
groups.  This was the case for the CPMG and NOSY spectra and was confirmed when the 
two cell lines were considered individually suggesting that FGF does not significantly alter 
the metabolic profile of the cells under the experimental conditions in question. 
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Figure 6.3 - The effect of FGF on the metabolic profile of SW480 and SW620 cells 
No PLSDA model could be generated.  R2Y is shown in green and Q2 in blue.  
 
6.3.3 Time related changes in the metabolic profile of control cells 
To establish the time related metabolite profiles for the cells, a PLSDA model was 
constructed using FGF treated and control cells with time group used a classifier.  Both cell 
lines were considered together.  A robust model was generated showing a clear and 
progressive time related change in the metabolite profile of the cultured cells.  Model 
statistics varied depending on the scaling strategy utilised but baseline noise made extraction 
interpretation of the loadings impossible and so un-scaled, centred data was used (Figure 6.4).  
Loadings plots were examined to determine those metabolites responsible for group 
separation and revealed that with increasing time, lactate (δ1.32) and alanine (δ1.47) both 
increased.  Glucose resonances (δ3.38-3.5) was reduced at later time points.  Changes were 
seen in the region of the spectra representing choline containing compounds:  choline and 
phosphocholine decreased as time progressed and glycerophosphocholine increased.   
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Figure 6.4 - Time related metabolic changes in control cells 
The PLSDA scores plot shows a clear discrimination between the untreated and FGF treated 
cells over the time course of the experiment.  R
2
Y=0.288, Q
2
=0.207, p<0.001.  The loadings 
plot reveals this to be due to increases in lactate and alanine and a decrease in glucose over 
time.  The relative amounts of choline and phosphocholine to glycerophosphocholine 
decrease as time progresses.   
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6.3.4 Metabolic response to 5-FU chemotherapy 
To compare the response of the cell types to 5-FU chemotherapy PLSDA models were 
constructed comparing control cells with those pre-treated with 5-FU.  Initially, separate 
models were constructed for each cell line but both appeared to separate along similar 
metabolites, therefore the cell lines were combined to create a more powerful model (Figure 
6.5).   
A robust model was generated that showed little overfit.  As expected, the scores plot 
revealed that control cells and those pretreated with 5-FU separated clearly in the first 
component.  In addition, a clear and progressive time related separation was observed in the 
second component although this was most pronounced in the control cells. 
The loadings plot showed a number of metabolites responsible for the separation of treatment 
groups.  A number of these are annotated in Figure 6.5 and a full list of those most 
significantly contributing to the class separation is given in Table 6.1.   
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Figure 6.5 – Metabolic response of SW480 & SW620 cells to chemotherapy 
The scores (A) and loadings (B) plots for a PLSDA model discriminating SW480 & SW620 control 
cells from those pre-treated with 5-FU.  All time points were included in the analysis.  Data was mean 
centred and Par scaled.  Model characteristics were R
2
Y=0.73,Q
2
=0.54 p<0.001.   
A 
B 
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Metabolite  
(number of peaks identified) 
Scores 
(mean w*c[1] ± S.D.) 
Fatty acid (5) 5.16 ± 0.74 
Branched chain amino acids (9) -6.24 ± 1.34 
Lactate (6) -14.1 ± 9.98 
Alanine (2) -14.35 ± 1.2 
Acetyl-group (1) 7.10 
Proline (11) -6.9 ± 1.02 
Glutamate (4) -7.075 ± 0.87 
Glutamine (3) 5.27 ± 1.08 
Citrate (5) -6.76 ± 1.14 
Sarcosine (1) 10.4 ±  
Lysine (2) -5 ± 0.28 
Phenylalanine (3) 5.03 ± 0.35 
Phosphocholine (1) 8.60 
Glycerophosphocholine (1) 17.70 
Glucose (33) 8.11 ± 2.07 
Methanol (1) 10.50 
Glycine (1) -18.40 
Unknown_a (2) 6.4 ± 0.57 
Unknown_b (1) -5.70 
Unknown_c (1) -4.80 
Table 6.1 - Metabolite changes in response to 5FU chemotherapy 
Loadings coefficients (w*c) were calculated for the metabolites contributing to the changes 
seen in response to 5FU as described in section 3.2.2.  The coefficients relate to the 1
st
 
principle component and a positive value is associated with 5FU treatment.  
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A number of the metabolites responsible for the separation could be confidently assigned.  
Lactate was reduced in cells pre-treated with 5-FU and a corresponding increase in glucose.  
A number of amino acids including the branched chain amino-acids could be confidently 
assigned and levels were generally reduced in 5-FU treated cells.  The single exception to this 
was a multiplet seen  δ2.42-2.48 which was increased in 5-FU treated cells.  Whilst the 
chemical shift and morphology of the multiplet suggested it represented glutamine, given that 
its appeared to show an opposing change to the other amino acids its assignment was 
confirmed with STOCSY (Figure 6.6) where other known glutamine multiplets at δ2.10-2.15 
and δ3.75-3.78 showed a high degree of correlation with the driving peak reinforcing the 
assignment of glutamine to this peak.   
 
 
Figure 6.6 – STOCSY of glutamine 
STOCSY plot of 5FU treated cells correlating to the proposed glutamine driving multiplet at 
δ2.42-2.48  
 
Choline and phosphocholine both increased in cells treated with 5-FU along with fatty acid 
metabolites and a multiplet tentatively assigned to sarcosine.  Several resonances could not be 
positively assigned but were included in further analysis.   
glutamine 
 
glutamine 
 
glutamine 
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Broadly, the changes observed in response to 5FU treatment reciprocated those seen by 
control cells over time. 
This may therefore represent the number of living cells alive at the time of sampling i.e. more 
living cells at later time points in control cells and less living cells alive in 5-FU treated 
groups.  To test this, a PLSDA model was constructed to examine the effect of pre-treatment 
with 5-FU over time.  As time progressed, total living numbers of cells in the 5-FU treated 
group fell, whereas in the control group cell numbers rose.  Nonetheless, 5-FU treated cells 
exhibited similar time related changes to control cells i.e. an increase in lactate and alanine 
and a decrease in glucose and choline containing compounds.  In addition, the same change 
in choline derivatives was observed over time as with control cells i.e. an increase in GPC 
and decrease in choline and PC.  These identical time related changes occurred in the 
presence of opposite effects in cell number and would therefore suggest that they are not 
simply due to cell death (Figure 6.7). 
  
157 
 
 
Figure 6.7 – Time related changes observed in 5-FU treated cells 
As time progressed both cell lines exhibited an increase in lactate and alanine and a decrease 
in choline containing compounds.   
 
6.3.5 Differential response of cell lines to treatment groups 
In order to determine the differential response of the SW480 and SW620 cell lines to 
treatment, models were constructed comparing the two cell lines for each of the four 
treatment groups.  Robust models were constructed for each of the four groups but all 
appeared to separate on the basis of similar metabolites.  Some of these were the same as 
those seen in the time based separation for the cells previously.  Choline and phosphor-
choline were increased in SW620 cells along with lactate and alanine.  Myoinositol was also 
higher in SW620 cells.  This pattern persisted across all four treatment groups (Figure 6.8). 
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Figure 6.8 – PLSDA loadings plots of the four treatment groups separated by cell type 
Loadings coefficient plots for the four treatment groups classified according to cell type.  
SW620 cells are in the upper right corner and SW480 cells in the lower left corner.  
Discriminating metabolites were similar across all four groups and dominated by choline 
containing compounds, myoinositol lactate and alanine which were higher in SW620 cells.  
6.3.6 The effect of treatment group on cell lines 
When compared, the differences between cell lines persisted across all 4 treatment groups 
suggesting the metabolite profile of each group is similar.  In an attempt to test this, models 
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were constructed for each cell line using the treatment groups as classifiers.  In both models 
the samples clustered into 2 groups: the control and FGF treated cells clustered together and 
the 5FU and 5FU+FGF treated cells also clustered.  There was no separation seen between 
the control and FGF treated cells, nor between the 5FU and 5FU+FGF treated cells in either 
cell line (Figure 6.9). 
 
Figure 6.9 – Treatment related differences in SW480 and SW620 cells 
A PLSDA scores plot for the 2 different cell lines using treatment group as a classifier.  In 
both cell lines, control and FGF treated cells clustered together as did 5FU and 5FU+FGF.   
 
The models were then reconstructed but excluding the control and FGF group in the hope that 
it was possible to discriminate between the 5FU alone and the cells treated with 5FU+FGF.  
It was impossible to construct a PLSDA model capable of discriminating between those 
SW480 cells treated with 5FU and the FGF/5FU group.  Both NOSY and CPMG spectra 
were utilised in attempting to construct the models.  This would imply there is no significant 
difference in the metabolite profiles of the groups and would be consistent with the lack of 
survival advantage seen in this cell line when pre-treated with FGF.   
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With the SW620 cells, although no PLSDA model could be generated using the CPMG 
spectral data, a model was generated with the NOSY spectra (p<0.05) and is shown in Figure 
6.10.  Interpretation of the loadings plot was challenging, as the UV scaling used to generate 
the model had given rise to amplification of the baseline noise seen in the spectra.  
Nonetheless, there appeared to be distinct changes in the choline peaks.  Those cells pre-
treated with FGF had higher levels of those metabolites a 3.23 and 3.24 thought to represent 
phosphocholine and glycerophosphocholine respectively.  There was a reciprocal decrease in 
the resonance at 3.21 which likely represents choline. It was not possible to precisely assign 
the variables responsible for the class separation, but as they appeared to be around the region 
of the choline containing compounds and the changes were not the same as those observed in 
SW620 cells in response to 5-FU chemotherapy alone or in those control cells over time were 
examined for changes in this region over time. 
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Figure 6.10 - Metabolic change conferred by FGF induced chemoresistance in SW620 
cells 
PLSDA scores and loadings plots of a model showing the effect of FGF on the metabolic 
profile of SW620 cells treated with 5FU chemotherapy constructed from the NOSY spectra.  
Cells treated only with 5FU are shown in black and those pre-treated with FGF in green.  
R2=0.253, R2Y=0.115 p<0.05. 
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Figure 6.11 shows the choline containing compound region of the spectra obtained for the 
SW620 cells for the two different treatment groups: 5FU and 5FU+FGF.  No clear 
differences appear between them.  Choline and phosphocholine appear to decrease with time 
whilst glycerol-phosphocholine increases with time – the same changes seen in the control 
cells.   
 
 
 
Figure 6.11 – Response of choline containing compounds in the SW620 cells to 5FU and 
FGF+5FU 
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6.4 Summary 
Control cells showed distinct time related changes that persisted across all treatment groups, 
and were largely dominated by changes consistent with the normal process of cellular 
glycolysis.  A reduction in intracellular glucose was seen as well as an increase in lactate over 
the course of the 96 hour incubation period.   
When the cells treated with 5FU were compared with control cells, a reduction of lactate was 
seen along with a corresponding increase in glucose.  The total number of cells decreases 
with time due to the treatment with chemotherapy, and cells are killed through apoptosis with 
resulting release of their contents into the surrounding media. As a consequence, the total 
amount of intracellular lactate would be lower in the 5FU treated cells.  As the experiment 
examined cellular extracts rather than media this may explain the lower levels of lactate.  
However, spectra were normalised to their median fold change and therefore, as total 
metabolite levels would also have fallen in the 5FU treated group, the lower level of lactate, 
and indeed the higher level of glucose may in fact be relative and represent an inhibition of 
cellular metabolism, including glycolysis, prior to cell death.    
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7 Discussion 
This chapter discusses in detail the findings in the preceding results sections and considers to 
what extent the original aims have been met.   
7.1 The Metabolic Phenotype of Colorectal Cancer (Aim 1) 
7.1.1 Does Colorectal Cancer demonstrate a metabolic phenotype distinct from 
normal tissue?  
1
H NMR analysis of colorectal tissue samples revealed a number of distinct metabolites and 
principle component analysis was able to robustly discriminate against malignant and normal 
tissue based on the spectra obtained with clear class separation seen on principle component 
analysis.  As an ‘unsupervised’ pattern recognition technique, the models constructed in PCA 
have no a priori knowledge of classes being separated.  This has been demonstrated before 
with 
1
H MAS and GC/MS in a study with a similar number of patients but fewer metabolites 
were identified
100
. 
In this study, a colorectal metabolic phenotype emerged of increased anaerobic glycolysis, 
increased amino acid turnover and a distinct pattern changes in levels of choline containing 
compounds.   
7.1.2 What are the metabolic characteristics of colorectal cancer tissue? 
The Warburg effect  
Significantly increased levels of lactate associated with significantly decreased levels of 
glucose in the malignant samples was identified and is an expected finding that has been 
demonstrated in other tumour types including colorectal malignancy
100
 
149, 150
.   
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Like all  rapidly proliferating cells, cancers demonstrate an increased uptake of glucose which 
can be metabolised through glycolysis to pyruvate. In normal cells this enters the Krebs cycle 
where it may be metabolised into Acetyl-CoA for amino-acid synthesis or citrate for the 
production of lipids.  Pyruvate may also be converted, anaerobically, to lactate.  This 
conversion of pyruvate to lactate is required to regenerate NAD+ for ongoing glycolysis and 
occurs in all cells but in normal tissue, most glucose is metabolised aerobically and ultimately 
ends up in the TCA cycle with a minority being converted to lactate.  In malignant (and some 
normal rapidly proliferating) cells, this ratio of anaerobic/aerobic glucose metabolism is 
reversed with the majority of glucose being metabolised anaerobically via fermentation rather 
than via oxidative phosphorylation.  This anaerobic metabolism is less efficient in terms of 
energy production yielding significantly less ATP per molecule of glucose metabolised.    
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Figure 7.1 - Glycolysis in normal and rapidly proliferating tissue 
From Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: 
the metabolic requirements of cell proliferation. Science 2009; 324(5930): 1029-33.  
Reprinted with permission from AAAS. 
In normal tissue, the presence of oxygen allows glucose to be metabolised to pyruvate and 
thence, via oxidative phosphorylation, to carbon dioxide yielding large amounts of ATP.  In 
cancer (and some rapidly proliferating normal tissue), the vast majority of glucose is 
metabolised anaerobically to lactate.  
 
 
In this study, two TCA cycle intermediaries – fumarate and isocitrate – were identified and 
quantified and were summed together to provide an indicator of TCA cycle activity.  In the 
absence of corroborating information such as protein expression or adjacent metabolic 
pathways it is difficult to attribute changes in levels of individual metabolites to particular 
changes inpathway activity.  Nonetheless.  The significant fall in TCA cycle intermediary to 
glucose levels seen in malignant tissue is supportive if not conclusive evidence of 
downregulation of this pathway.    
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The advantage that anaerobic glycolysis provides is that it can occur in an hypoxic 
environment.  Unlike oxidative phosphorylation, glycolysis and fermentation can occur in 
hypoxic tissues.   
As observed in a number of other tumours and indeed in normal tissue, the partial pressure of 
oxygen in colorectal adenocarcinomas is highly variable and bears little correlation to the 
local blood flow.  In central necrotic areas the oxygen concentration is often zero thus steep 
gradients are seen.  This observation has given rise to the theory that the Warburg effect is an 
adaptation to tumour hypoxia or alternatively the more contemporary view that the switch to 
glycolytic respiration has been linked to activation of oncogenes and inactivation of tumour 
suppression genes suggesting that it is intrinsically linked to malignant transformation.    
 
With only the metabolic endpoints to examine in this study it is impossible to advance the 
theory that this ‘metabolic reprogramming’ may be responsible for the Warburg effect in 
colorectal cancer rather than an adaptation to the micro-environment.  Although it by no 
means offers a convincing argument, it is interesting that in the single specimen that 
contained a colorectal adenoma (patient 7), the ratio of lactate:glucose was increased 3 fold in 
tumour tissue, a similar fold change to that seen in the malignant samples as a whole (data not 
shown).  Whether or not the particular sample under study represented adenoma or the focus 
of cancer inside it is unclear without specifically examining the histology of the of that 
particular sample following NMR analysis.  It seems statistically likely however that it 
represented benign adenoma rather than the small focus of malignancy within it.     
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An increased pool of mobilised free amino acids 
Amino acid resonances were prominent in all of the spectra from both normal and malignant 
tissue.  In total, 11 amino acids were identified and all showed an increase fold change in 
malignant tissue with the exception of glutamine.   
Cancerous cells are known to utilise amino acids as energy precursors (reviewed in 
151
) and 
therefore a freely available pool is vital for their metabolism.  Free amino acids circulate in 
the bloodstream and can be uptaken into tumour cells this way.  Alternatively, and where 
blood supply to the cancer is poor, degradation of proteins can supply a freely available pool 
of individual amino acids.  De novo amino acid synthesis also occurs via the TCA and other 
pathways.   8 of the basic amino acids cannot be synthesised in humans and must therefore be 
derived from the diet or protein catabolism.  5 of these essential amino acids were identified 
in the colorectal samples.  Isoleucine, valine and phenylalanine showed a significant increase.  
Leucine showed an increase that just failed to meet significance and lysine demonstrated a 
modest and insignificant reduction in malignant tissue.   The changes seen in these essential 
amino acids cannot be due to increased TCA cycle activity and must be derived from 
increased protein breakdown or absorption – the former seeming much more likely.   
Of the non-essential amino acids identified, glutamate showed a significant increase.  The 
remainder showed a non-significant increase with the exception of glutamine – the only 
amino acid to show a significant reduction in malignant tissue.  The preference of cancer cells 
for glutamine for energy generation is established 
152
 and occurs via the TCA cycle after the 
breakdown of glutamine to glutamate.  The significant reduction in glutamine seen in 
colorectal tissue could therefore be due to increased activity of the enzyme glutamine 
synthetase with resulting rapid depletion of free glutamine.  If this is the case however, 
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increased levels of TCA cycle intermediaries might be expected as glutamate undergoes 
transamination to form α-ketoglutarate and enter the cycle.  This was not the case.   
Alterations in choline metabolism 
Choline is a water soluble essential nutrient absorbed into cells prior to synthesis into 
phosphocholine and then phosphatidyl choline, an essential component of cell membranes.   
Choline containing compounds have previously been observed to be elevated in multiple 
different cancer types (reviewed in 
153
) Three choline containing compounds were identified 
in the tissue spectra – choline, phosphopholine (GPC) and glycerophosphocholine (PC) and a 
significant increase was seen in the malignant tissue in all three choline containing 
compounds.  The GPC/PC ratio was however significantly lower in malignant tissue than that 
seen in normal tissue.  Free choline enters the cell and is metabolised to phosphocholine 
before being utilised in the formation of the membrane phospholipid phosphatidylcholine.   
Upregulation of choline transport and choline kinase are common reatures in malignancy 
154
.  
In addition, in prostate cancer which are known to be associated with increased choline levels 
155
, the development of choline tracers for use in PET CT has shown to be more sensitive than 
bone scanning for the detection of bony metastases 
156
.  Changes in choline metabolism have 
been less well described in colorectal cancer.  Nonetheless the consistent changes it has 
demonstrated in this study yield a potentially interesting avenue for exploration as potential 
biomarker of the disease.    
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A redeuction in myo-inositol levels is seen 
A significant reduction in myo-inositol levels was observed in in the cancer specimens 
compared to normal mucosa.  Myoinositol the most commonly occurring steroisomer of 
inositol, a polyalcohol of cyclohexane and occurs abundantly in a number of human tissue 
types including the gastrointestinal tract
157
.  It is synthesised from glucose-6-phosphate, 
mainly in the kidneys with its presence in other tissues mainly resulting from circulatory 
uptake
157
.  It plays an important role  in cell membrane structure as a precursor of 
phosphatidylinositol, a key membrane constituent in eukaryotic cell membranes
158
.  Perhaps 
more importantly however, is its role in a variety of cell signalling pathways where it is 
involved in pathways regulating cellular replication, and regulation
159
. 
Myoinositol has previously been shown to be reduced in colon cancer tissue 
104
 as well as 
gastric cancer 
160
 and the relatively higher levels seen in normal tissue could be related to the 
downregulation of various signalling pathways known to occur in colorectal carcinoma.  It 
seems unlikely however that such a significant difference between tumour and normal tissue 
would be seen as a result of changes in signalling pathways.   
The cell membrane of normal colonic mucosa is known to contain high levels of myo-inositol 
and scyllo-inositol
161
, where they play a role in regulating osmotic stress 
162
.  Both were 
significantly reduced in cancer samples compared with normal tissue  in keeping with 
findings of previous studies.
100,103, 104
  Another regulator of osmotic stress is  Taurine which 
regulates osmotic stress in the shorter term.
162
  Unlike the inositols identified however it was 
significantly increased in the mucosa of the colon cancer samples, which is also previously 
described
103,104
.  These reciprocal changes in regulators of osmotic stress may therefore 
represent a dysregulation of osmolyte function in cancer cells.  One such effect of this may be 
on apoptosis where taurine has been implicated in cell shrinkage prior to apoptosis. 
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7.1.3 Conclusion 
A distinct metabolic phenotype was seen to be associated with colorectal cancer in this study.  
Largely, this phenotype related to the increased energy requirements of malignant tissue, 
namely a demonstrable increase in anaerobic metabolism as well as an increase in free 
amino-acids.  Changes in choline metabolism were interesting and consistent and present 
interesting targets for possible biomarker development. 
7.2 Can metabonomics contribute to colorectal cancer staging? (Aim 2) 
In the data presented in chapter 7, 
1
H MAS NMR spectroscopy was utilised in order to 
externally validate a series of PLSDA models and putative metabolic markers of disease 
indices in colorectal cancer with mixed success.  Predictive models could be generated 
capable of discriminating between cancerous and normal tissue which appeared to be robust 
but when validated against an external data set showed lower predictive ability.  Attempts to 
generate models predictive of pathological stage and other pathological and clinical state 
were largely unsuccessful. 
7.2.1 Can the metabolic profile of colorectal tissue be used to discriminate between 
healthy and cancerous tissue? 
The ability of NMR spectroscopy to discriminate between cancerous and normal colorectal 
tissue has been shown by other authors
100, 102-104
 but none have used a separate set of samples 
to externally validate their data.  Studies using serum, urine and faecal water however have 
attempted to externally validate their models with similary predictive abilities to the training 
data
110, 117, 119
.  Utilising a GC-MS platform, Cheng et al reported areas under the ROC of 
0.993 and 0.998 for the training and validation set respectively.  Conversely, Ritchie et al 
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reported a slight reduction of the predictive ability of their model when externally tested, 
which yielded AUCs of 0.91 and 0.87 for training and validation set respectively. 
In the previous chapter, a number of different amino acids were shown to be significantly 
increased in the malignant tissue.  Of these, only taurine and glutamate appear to be strong 
contributors to the class separation observed in the discriminatory models implying that 
although there is a significant change in the ‘average’ levels of the other amino acids, their 
variation between samples means they are not strong contributors towards the class 
separation.  Other significant contributors were myo-inositol and lactate which have been 
discussed previously. 
The presence of polyethylene glycol (PEG) in the tissue samples arises as a result of its use as 
a bowel preparation solution prior to surgery.  Its presence is unsurprising but its dominance 
in the class separation between normal and cancer tissue is unexpected where higher levels of 
PEG were strongly correlated with the normal tissue type suggesting it is preferentially 
absorbed in this tissue.  The fact that its mean elevation in normal tissue does not meet 
statistical significance is probably due to the fact that it is generally only given for left sided 
resections and therefore, its absence in normal right sided resections gives rise to a high 
variance overall.  PEG is a relatively high molecular weight polyether whose absorption will 
depend on the permeability of the membrane it is crossing and its absorption has been shown 
to vary with the permeability of the gut mucosa in humans 
164
.  Although gut barrier function 
is known to be decreased in the early stages of colorectal cancer development 
165
, the actual 
tumours evaluated in this study would appear to have reduced membrane permeability, 
evidenced by the reduced absorption of PEG.   
It should be noted that this study compared cancerous tissue with normal tissue from the 
same piece of bowel.  Fundamentally this may not the same as comparing the malignant 
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tissue with a piece of normal bowel.  Obtaining colonic mucosa from normal subjects is 
generally not feasible and likely limited to obtaining endoscopy biopsies from subjects who 
turn out to be normal but the opportunity to collect entirely normal tissue is very limited.   
7.2.2 Can the metabolic phenotype differentiate between cancers by pathological 
stage?  
It was impossible to develop models predictive of pathological tumour stage, or the presence 
or absence of a number of histological prognostic features.  Whilst it was possible to generate 
a model predictive of the presence or absence of positive lymph nodes, it was weak, and 
external validation yielded no predictive ability.  The inability of 1H NMR to predict surgical 
stage has been identified in other tissue based studies 
100
 
104
 who used a similar number of 
specimens of cancer tissue.  To date, the only convincing data on stage prediction is from a 
serum based study that utilised 1H NMR to discriminate between patients with liver 
metastases and those without 
112
.   
It may be that the relatively low number of specimens was responsible for the failure to 
generate discriminatory models for stage and other histological data but even when stages 
were grouped, PLSDA was unable to discriminate between low and high grade cancers.  
Alternatively, it may be that whilst the metabolic phenotype changes in a consistent way in 
response to cancer it does not continue to change in an orderly and consistent way as cancer 
progresses.  A hallmark of cancers of all types is deregulation of many different cellular 
processes leading to a heterogenous mass of tumour cells.  Whilst tight homeostasis occurs in 
healthy cells, leading to a distinct metabolic phenotype this phenotype does not progress 
uniformly across tumours as they advance in stage and grade.  It would be interesting to 
characterise pre-malignant colorectal polyps using the methods in this study.  This group are 
known to be a distinct entity with discreet molecular characteristics that occur in a 
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progressive fashion and accordingly may be expected to display a metabolic phenotype 
distinct from that of normal and cancerous tissue.   
The heterogeneity of malignant tumours is well recognised and has been demonstrated using 
a variety of outcomes including the molecular events such as the k-ras and p53 gene 
mutations 
166
 as well as the tumour microenvironment (reviewed in 
167
).  In rats, tumour 
hypoxia was found to be high levels of intratumoral variability in several different tumour 
types 
168
.  Given its central role in determining the balance between aerobic and anaerobic 
respiration, the heterogeneity in the degree tumour hypoxia will likely be reflected in the 
metabolic phenotype.  In this study, a single sample of tumour tissue was analysed with 
1
H 
NMR analysis and will therefore only reflect a single area of the tumour.  For differences in 
histological stage to be detected they would have to be consistently represented throughout 
the tumour.  
A recent study in the New England Journal of Medicine examined intratumour heterogeneity 
using exome sequencing on multiple spatially separated samples obtained from a primary 
renal carcinoma and its associated metastatic sites 
169
.  Significant intratumour heterogeneity 
was observed within the primary tumour in addition to across the metastatic sites.  It seems 
likely therefore that this genetic heterogeneity also manifests as heterogeneity within the 
metabolome and it may be that the best opportunity to identify such differences lies in the 
analysis of biofluids such as plasma, urine or faecal water. 
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Figure 7.2 – Genetic intratumour heterogeneity 
Reproduced with permission from Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor 
heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 
2012; 366(10): 883-92.  Copyright Massachusetts Medical Society. 
7.2.3 Can the metabonomic phenotype differentiate by cancer specimens by node 
status? 
The ability of PLSDA to discriminate between nodal status (positive or negative) was 
interesting and does not appear to have been attempted before.  Although cross-validation 
appeared to demonstrate that the model discriminating nodal status in tumour specimens was 
relatively robust, it did not demonstrate predictive ability when tested with a validation data 
set.  This may be due to the different platform used or alternatively may reflect an over-fitting 
of the original model despite this not being evident at the time.  It seems unlikely that the 
model represents a true ability to discriminate nodal status when it was impossible to 
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distinguish between tumour stage.  In addition, the metabolites contributing most strongly in 
favour of node positive status were in some cases those that appeared to be significant 
predictors of tumour tissue in the tumour vs normal models.  Further analysis utilising a 
larger sample set would be helpful in determining if this finding is in fact an artefact.  If this 
finding were to be reproducible it could have significant potential benefits in providing early 
prognostic information from a luminal biopsy alone that may prove to be more accurate than 
current radiological staging.  
7.2.4 Can any putative biomarkers be validated using an external test data set? 
The difference seen in AUCs for the training and validation set could be due to a number of 
different factors.  Fundamentally, MAS is a different analytical platform from the 
1
H NMR 
spectroscopy performed on the tissue extracts.  Although much of the resulting data is 
similar, differences exist in the spectra due to differences in the sensitivities of the platforms.  
Although attempts were made to overcome this by normalising the spectra to the median fold 
change, this only has the effect of normalising the spectra to equivalent amplitudes.  
Sensitivity differences for the two platforms in detecting particular metabolites will still 
persist – for example the NMR analysis of the tissue extracts revealed much better resolution 
of the 3 different choline containing compounds (δ3.18-3.23) than MAS analysis.  
Additionally, the pH shifts seen in the two different platforms were subtly different and made 
precise overlaying of the spectra impossible.  This latter point should have been overcome 
when integral regions were utilise for the generation of the predictive model and then their 
subsequent testing but this approach results in the loss of a significant amount of spectral data 
and as a consequence the predictive models generated were much weaker.   
The decision to utilise a different analytical platform, in the form of MAS, for the validation 
set was made as an attempt to demonstrate the ability of 
1
H NMR to reliably generate a 
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predictive model capable of discriminating between tissue types.  The relatively small 
reduction in AUC seen when tissue was analysed using MAS is evidence that the metabolic 
phenotype of the tissue is relatively consistent when measured across different experiment 
types and can potentially therefore be evaluated in a statistical model generated using other 
methods.  Furthermore, as MAS is a non-destructive method of analysis, it bears closer 
resemblance to any possible in vivo applications that may ultimately be developed for 
colorectal cancer biomarkers for example by utilising existing MRI technology. 
Caution must exist when interpreting the predictive ability of the model on the external 
validation set used in this study.  The external validation set here comprised samples taken 
from the same specimens as that used in the training sets.  Although a separate tissue sample 
was taken from the specimens in the validation set, it is likely to contain the same metabolic 
phenotype as the sample used in the training set and therefore cannot be regarded as true 
external validation.  A much more robust external validation would have utilised samples 
taken from entirely different patients altogether but due to the relatively small number of 
patients recruited in this study this was not possible.   
7.2.5 Conclusions 
It was expected that there would be demonstrable differences between tissue from different 
anatomical locations but this was not the case. Whilst the two sites contain the same cell type 
in both normal and cancerous states, a number of features give rise to the expectation that 
they should contain a distinct metabolic phenotype.  The gut microflora is known to vary by 
the anatomy of the lower gastrointestinal tract
170
 and it could be expected that these 
differences are manifest in the metabolite profiles of different locations.  It was hypothesised 
that these different profiles would converge towards a single phenotype in malignant tissue 
but this was not the case.  A number of the pathological specimens were classified as “recto-
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sigmoid”.  It is unclear exactly where these specimens arose from and accordingly whether 
they should in fact be characterised as colonic or rectal specimens.  When these were 
excluded from the analysis and only true colon are rectal samples compared the number of 
samples was too low to generate a meaningful model.  When classified as rectal specimens 
however it was possible to generate a very weak model that discriminated on the basis of type 
but this did not reach statistical significance and could not be tested with the external 
validation set.     
A number of experimental factors may have contributed to the failure to generate 
discriminatory models in this study.  Spectra were manually baseline corrected and subtle pH 
shifts meant that they could not be precisely overlaid.  They were normalised to the median 
fold change of the spectral signal which, whilst an established method, may be suboptimal if 
single metabolites in particular samples were particularly prevalent 
171
.  Alternative methods 
of normalisation, such as to total protein concentration of the sample could be attempted in 
future.   
This study has demonstrated 
1
H NMR spectroscopy as a viable method for discriminating 
tumour from normal in colorectal tissue utilising PLS regression analysis.  It was unable to 
discriminate tissue based on other factors except in a few cases which may not be 
reproducible.  It utilised a relatively small number of samples which may have contributed to 
the failure to discriminate tissue based on clinical and pathological data.  Future 
investigations should be based on a larger sample size, possibly utilising biofluids and be 
externally validated utilising the same platform in a separate sample set.  Healthy controls 
should be used to provide normal samples.    
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7.3 To evaluate the metabolic changes seen in colorectal cancer chemoresistance using 
metabonomics (Aim 3) 
Control cells showed distinct time related changes that persisted across all treatment groups, 
and were largely dominated by changes consistent with the normal process of cellular 
glycolysis.  A reduction in intracellular glucose was seen as well as an increase in lactate over 
the course of the 96 hour incubation period.   
Of the amino acids, a marked increase in alanine was seen over the time course of the 
experiment whilst similar increases were not observed in the other amino-acids.  Glutamine is 
a conditionally essential amino acid that is required for stable cell culture due to its high 
levels of utilisation in cellular processes.  When added to culture medium however it is 
unstable, rapidly degrading into ammonia and pryyolidone carboxylic acid as by products 
172
.  
To overcome this, GlutaMAX
TM
 was added to the culture media.  It is more stable in media 
and after absorption into the cell is cleaved into alanine and glutamine.  Whilst glutamine is 
consumed at rapid rate as a cellular energy source, nitrogen donor and protein synthesis, 
alanine is less so and as a consequence it is likely to accumulate over the course of time as 
seen here 
173
.    
Choline is an essential nutrient required for the synthesis of phosphatidylcholine, an essential 
component of cell membranes.  This occurs via the intermediary, phosphocholine, and the 
reduced levels of both compounds seen over the time course of this experiment are as as 
expected in the absence of fresh media.  Glycerophosphocholine (GPC) is a degradation 
product of phosphatidylcholine, and levels increased over time in contrast to the other two 
choline containing compounds, likely as a result of increased cell membrane breakdown.   
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7.3.1 What metabolic changes are associated with 5FU chemotherapy? 
When the cells treated with 5FU were compared with control cells, a reduction of lactate was 
seen along with a corresponding increase in glucose.  The total number of cells decreases 
with time due to the treatment with chemotherapy, and cells are killed through apoptosis with 
resulting release of their contents into the surrounding media. As a consequence, the total 
amount of intracellular lactate would be lower in the 5FU treated cells.  As the experiment 
examined cellular extracts rather than media this may explain the lower levels of lactate.  
However, spectra were normalised to their median fold change and therefore, as total 
metabolite levels would also have fallen in the 5FU treated group, the lower level of lactate, 
and indeed the higher level of glucose may in fact be relative and represent an inhibition of 
cellular metabolism, including glycolysis, prior to cell death.    
A number of amino acids were identified and these were generally reduced in 5FU treated 
cells with the exception of glutamine.  The enhanced role of glutamine for amino acid 
synthesis and other metabolic pathways in rapidly dividing cells such as cancer is established 
174
.  Therefore, again as with glycolysis, an arrest of the cell cycle and consequent reduction 
in cellular metabolism is consistent with a reduction in glutamine utilisation as is the 
reduction in the other amino acids identified. 
Myoinositol levels were increased in cells pre-treated with 5-FU.  Amongst its other 
functions, insitols are metabolised to form Phosphatidylinositol.  These compounds are 
involved in the PI3K pathway, an intracellular signalling pathway that is known to be 
involved in the regulation of apoptosis in colorectal cancer 
175
 
176
.  Both SW480 and SW620 
cells constitutively express the PI3K protein and inhibition leads to increased apoptosis in 
both cell lines although to a greater extent in SW620 cells
177
.  Myo-inositol levels have been 
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shown to be increased in a prostate cancer cell line, also known to express PI3K, during cell 
cycle arrest 
178
. 
7.3.2 Is FGF induced chemoresistance associated with a distinct metabolic profile? 
The two cell lines appeared to separate on the basis of the same metabolites for all four 
treatment groups.  Choline, phosphocholine, lactate and alanine were all higher in the SW620 
groups across all treatment groups in much the same way they were across the time domain.  
These findings appear to suggest a higher level of metabolic activity in the SW620 cell line, 
consistent with its enhanced malignant potential, and has been seen previously where this cell 
line has demonstrated enhanced polyamine metabolism compared to the primary SW480 cell 
line 
179
.   
Although the two control groups (untreated cells and FGF treated cells) separated from the 
treatment groups (5FU and 5FU+FGF) separated in the models constructed, it was impossible 
to discriminate between them in either group.  Whilst this might be expected in SW480 cells 
for which no protection agains chemotherapy induced apoptosis is seen with FGF, it was 
unexpected with the SW620 cells.  Although a weak model could be constructed using the 
NOSY spectra of the latter cell type, it could not be translated into a clear difference in the 
metabolite profile of the 2 groups.  Furthermore it could only be demonstrated with the 
NOSY spectra, when scaled to unite variance.  Inherently more ‘noisy’ the separation may 
therefore have been an artefact due enhancement of the baseline noise seen in these spectra.   
7.3.3 Can metabonomics be used to explain the mechanisms associated with 
chemoresistance? 
Although the exact mechanisms by which FGF2 confers a chemoprotective effect on 
colorectal cancer cells is not fully elucidated, it is thought to act through modulation of 
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cellular apoptosis 
180
 
181
 and indeed work done by others in this department has demonstrated 
a reduction in apoptotic activity in cells pre-treated with FGF-2 
148
.  Apoptosis can be 
mediated via a number of signalling pathways and determining a mechanism for its action in 
this study was dependent on either identifying components of these pathways or alternatively 
deducing a mechanism by interpretation of its downstream effects.  The only potential 
precursor to a signalling intermediary identified in this study, myoinositol, showed a similar 
trend in cells treated with 5FU alone and those pretreated with FGF2.  Conceivably, the 
modulation of apoptosis is regulated by signalling intermediaries not detected by the platform 
used in this study.  Even if this were the case however, it would be expected to see a 
reflection of the downstream affects of reduced apoptosis.  As the chemotherapy group reflect 
reduced glycolysis, as well as reduced utilisation of glutamine, inhibition of this effect should 
potentially have been reflected by the FGF2 pre-treated cells clustering with the control cells 
in the SW620 group but this was not the case.  Possibly, despite exerting a chemoprotective 
effect, the FGF2 does not alter the inhibition of cellular metabolism apparently induced by 
5FU.   
7.3.4 Conclusions 
In this study, whilst a range of metabolites were identified, the panel represents a tiny fraction 
of the metabolites, chemical messangers and other molecules participating in cellular 
function.  Whilst the panel appeared to be suitable for identifying the broad changes 
associated with cellular energy processes such as glycolysis and amino-acid metabolism, it 
would seem likely that they lacked sufficient power to detect more subtle changes occurring 
at a cellular messaging level.  Alternative NMR based strategies such as 
31
P or 
13
C NMR may 
be able to elucidate the molecules involved in these events.  
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7.4 Limitations 
Although there appears to be enormous potential for applications of the techniques employed 
in this thesis, certain limitations remain.  The experiments performed here were of relatively 
limited sample size, and the distribution of cancer specimens in some cases led to groups as 
small as 2 patients (e.g. Dukes A).  Larger sample sets may well be more powerful in eliciting 
variation in sample sets.   
Although biofluids were not assessed here, intrinsic variation exists within individuals 
depending on time of day, diet, drugs taken and a host of other factors.  This strength of 
metabonomics – to reflect the organism as a whole – could well be a weakness in this setting 
where, without large sample sizes, these intrinsic variations may overwhelm the subtle 
changes invoked by the disease process.  In addition, the natural variability between 
individuals such as plasma pH and diet could account for slight variation in chemical shift 
and potentially some of the variability between samples identified. 
The collection of samples intraoperatively leads to a number of potential confounders of the 
metabonomic phenotype identified.  As mentioned previously, variations in surgical 
technique lead to differences in the time taken to sample the specimen after the mesenteric 
blood supply is divided.  In some laparoscopic procedure, vessels are taken earlier, and as a 
consequence the sample will be ischaemic for a longer period of time than those samples 
taken from open cases when vessel division is often the final step.  These long ischaemic 
times may contribute to the Warburg Effect, seen in tumour samples in these experiments and 
attributed to the innate changes in cancerous tissue.  An alternative sampling strategy such as 
endoscopic sampling of tumour and normal tissue could eliminate this.   
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Low sensitivity is an inherent disadvantage of NMR spectroscopy. Metabolites in the mM 
and mid to high uM range can be detected, meaning that about 100 metabolites 
182
 can be 
detected in urine samples and even fewer in serum and intact tissue samples.
183
 As there are 
at least several thousand metabolites, this may be considered as the main drawback of the 
NMR approach to metabolomics. However, if NMR can be used to identify a biomarker by 
the analysis of a relatively small number of the most abundant metabolites, this may be 
considered an advantage whereas profiling thousands of metabolites would be complicated 
task. Furthermore, any metabolite that is detected in vitro by NMR spectroscopy could in 
theory be followed by in vivo studies using MRS.  
The experiments in this thesis were performed using on one-dimensional (1D) proton NMR 
spectra. The small spectral width of proton NMR spectroscopy means that most of the 
resonances of the detected metabolites are crowded within a narrow chemical shift range and 
are usually overlapping, leading to uncertainty in NMR signal assignments for different 
metabolites. 
The multivariate nature of NMR spectra requires pre-processing to filter out possible 
influences of orthogonal variations from the final result (for example, highly concentrated 
metabolites dominating the variance of subsequent principal component analysis).  However 
this pre-processing step has several drawbacks.  Binning is necessary to reduce the size of the 
data-set but this lowers the sensitivity where the peaks associated with weakly concentrated 
metabolites are obscured by variation in noise or where peaks are overlapping.   Whilst 
critical to provide objective comparisons between samples of different concentrations, 
normalisation can adversely influence multivariate data analysis, especially in samples that 
contain large amounts of a single substance 
138
. 
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With any multivariate analysis approach, the experimental design should include a ‘quality 
control metric’ 184.  The ideal quality control is a complete external data set, measured on the 
same platform.  This was not available in the experiments undertaken here due to the 
relatively small number of patients used and attempts to externally validate with the same 
patients using a different platform had mixed success.  Although cross validation was used, 
the models can still suffer from ‘over-fit’.  This is caused by the ability of algorithms such as 
PLS-DA to find solutions in some spaces where no real solution exists. For example, PLS-
DA can separate two groups comprised completely of random data to which the only solution 
is to demonstrate replication of the results in a blind, new dataset.
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Attempts were made to externally validate some candidate biomarkers utilising an external 
test set but as they were drawn from the same samples as the ‘training set’ they cannot be 
regarded as an external test set had they proved to validate the candidate biomarkers.  This 
makes it all the more surprising that the sensitivity and specificity achieved with this 
‘validation’ subset was so low.  Although measured on a slightly different platform (MAS 
compared to tissue extract NMR) the metabolites were identified and isolated and the lack of 
validation here would appear to be due to either heterogeneity in samples taken from the 
same specimen or a lack of reproducibility of the technique.  
7.5 Summary and Future Work 
Significant advances have been made in the management of colorectal cancer over recent 
decades but it continues to be a significant public health concern.  It often requires adjuvant 
treatment modalities that carry significant morbidity and frequently fail.  Lack of effective 
predictive biomarkers makes it challenging to identify those patients who will benefit most 
from adjuvant treatment and whilst a national screening program exists for the disease,  
patients continue to present at an advanced stage.  Furthermore, whilst much has been defined 
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regarding its molecular development, comparatively little is known about the mechanisms 
that mediate the aetiological factors involved in its development. 
Metabonomics is a relatively young scientific discipline that has shown potential in the 
development of both developing biomarkers as well as elucidating cellular mechanisms 
although has yet to materialise into fully translatable solutions to clinical problems. 
Compared to other disease processes, there has been little study of colorectal cancer using 
these techniques although this is increasing.  
As a disease that progresses relatively slowly, colorectal cancer outcome is closely related to 
the stage of the disease at which it is detected and earlier detection is likely to decrease 
mortality.  As an integral part of tumourigenesis, metabolism provides the energy 
requirements of cancer cells and is therefore integral to cancer pathogenesis. NMR-based 
metabonomics has the potential to identify biomarkers and also provide assessment tools for 
patients at different stages of the disease.   
This thesis attempts to apply 1H NMR spectroscopy and multivariate statistical modelling to 
a number of topical questions in the field of colorectal cancer.  It defines a distinct metabolic 
phenotype for the disease and while much of this was already described, demonstrates the 
capability of the analytical platform in detecting it.  In addition, the capability of 
metabonomics to predict the presence of cancer is presented and whilst disappointingly it 
could not be used to discriminate between tumours based on histological or other data, this is 
broadly in keeping with what other investigators have found for this and other cancers. 
Finally, attempts were made to utilise metabonomics to investigate the mechanism by which 
chemoresistance may be conferred by FGF-2.  The inability of the technique to determine a 
mechanism may be expected given the limited array of metabolites and further work could be 
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considered specifically targeting towards identifying cell signalling molecules thought to be 
involved in chemotherapy mediated apoptosis.   
A consistent theme through the results chapters is that whilst on occasion there are interesting 
a significant findings in terms of changes of metabolite concentrations, the lack of a more 
complete set of data means drawing definitive conclusions is impossible. Often only one or 
two metabolites in a pathway could be identified or be shown to be significantly changed to a 
given state.  The most useful studies in future are likely to be those that incorporate other 
analytical techniques such as genomic, and proteomic analysis as well as functional assays in 
order that changes in the metabolic endpoints can be corroborated with actual function.  A 
larger sample size is necessary to fully define some of the potential metabolite changes seen, 
and other analytical platforms such mass spectroscopy or phosphate or carbon NMR may 
provide further insight into the changes in some of the lower concentrations seen such as the 
nucleotides and their derivatives.  Only analysis of biofluids will offer a truly non-invasive 
test, but the large number of samples required for the definition of robust biomarkers must 
not deter future studies.   
True clinical applications of metabonomics have yet to be realised but its tantalising potential 
is driving an explosive interest in clinical studies across many medical specialties driven by 
the possibility of individually tailored therapy. 
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